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Abstract 
The approval of imatinib in 2001 marked a milestone in targeted therapy. Protein kinase 
inhibitors have revolutionized the cancer treatment since then. Progression free survival 
could be significantly prolonged in many cases. However, tumors often develop resistances 
during the treatment with kinase inhibitors. As consequence, most patients experience a 
relapse during initially successful therapy. Systemic adverse side effects are another drawback 
of kinase inhibitors. Thus, novel approaches in the field of protein kinase inhibitors are 
urgently required to improve the clinical outcomes. 
The present work describes development and characterization of novel photoactivatable 
prodrugs of several approved small molecule kinase inhibitors. Photoremovable protecting 
groups were therefore covalently bound to key pharmacophore moieties of active kinase 
inhibitors. The implementation of a protecting group distinctly diminished the biological 
activity of protected inhibitors. Directed light irradiation caused photoinduced cleavage of the 
protecting group. Active kinase inhibitors were released. The concept was successfully 
verified in vitro on approved kinase inhibitor vemurafenib. Spatiotemporal control of the 
photoinduced release of the active inhibitor could be demonstrated in cellular assays. The 
approach could be successfully transferred to further kinase inhibitors such as imatinib. 
However, limitations of the concept were also revealed. In line with this notion, a hitherto 
undescribed photoinduced conversion of approved inhibitor dabrafenib was demonstrated. 
The photoactivatable prodrugs of kinase inhibitors represent a powerful pharmacological tool 
for profound in vitro investigation of protein phosphorylation. However, further development 
with regard to physicochemical and pharmacokinetic properties is required prior to clinical 
applications. Novel approaches for targeted reactivation in deeper biological tissues are 
discussed at the end of the work. 
A side project of the present work was the characterization of novel PDGFRinhibitors. 
Potent and selective DFG-in and DFG-out inhibitors were compared in vitro. In particular, the 
DFG-out inhibitor 3 exhibited promising cellular activity and might be used for further lead 
optimization.  
  
  
  
Kurzzusammenfassung 
Die Zulassung von Imatinib im Jahr 2001 war ein Meilenstein in der Geschichte der gezielten 
Krebstherapie. Seitdem haben Proteinkinaseinhibitoren die Tumorbehandlung revolutioniert. 
Das Überleben vieler Krebspatienten wurde signifikant verlängert. Doch leider entwickeln 
Tumore während der Behandlung mit Kinaseinhibitoren oft Resistenzen, die in den meisten 
Fällen zu einem Rezidiv führen. Außerdem leiden viele Patienten an systemischen 
unerwünschten Arzneimittelwirkungen. Neue Konzepte auf dem Feld der Kinaseinhibitoren 
sind also nötig, um die therapeutische Effizienz und Verträglichkeit zu erhöhen. 
Die vorliegende Arbeit beschreibt die Entwicklung und Charakterisierung von neuartigen 
photoaktivierbaren Prodrugs von mehreren zugelassenen Kinaseinhibitoren. Dafür wurden 
photoabschaltbare Schutzgruppen kovalent an aktive Kinaseinhibitoren gebunden. Das 
Einbringen einer Schutzgruppe führte zur pharmakologischen Inaktivierung der Inhibitoren. 
Durch gezielte Lichtbestrahlung konnte die Schutzgruppe abgespalten werden. Die aktiven 
Wirkstoffe wurden dadurch freigesetzt. Am Beispiel des zugelassenen Kinaseinhibitors 
Vemurafenib konnte der Ansatz in vitro erfolgreich überprüft werden. Die zeitliche und 
räumliche Kontrolle der photoinduzierten Aktivierung wurde damit demonstriert. Das 
Konzept konnte auf weitere Kinaseinhibitoren wie Imatinib erfolgreich übertragen werden. Es 
wurden aber auch Limitierungen des Ansatzes gezeigt. So wurde eine bis dahin unbekannte 
photoinduzierte Umwandlung des zugelassenen Kinaseinhibitors Dabrafenib beschrieben. 
Die photoaktivierbaren Prodrugs von Kinaseinhibitoren stellen ein wertvolles 
pharmakologisches Werkzeug dar, um die Proteinphosphorylierung in vitro genauer zu 
untersuchen. Für eine klinische Anwendung ist eine Weiterentwicklung hinsichtlich 
physikochemischer und pharmakokinetischer Eigenschaften notwendig. Am Ende der Arbeit 
werden verschiedene Möglichkeiten der gezielten Aktivierung in tieferem Gewebe diskutiert. 
Im Rahmen eines Nebenprojekts wurden in dieser Arbeit potente und selektive PDGFR-
Inhibitoren charakterisiert. Dabei wurden DFG-in und DFG-out Inhibitoren verglichen. 
Besonders der DFG-out Inhibitor 3 zeigte eine vielversprechende zelluläre Aktivität und sollte 
für eine weitere Optimierung verwendet werden.   
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1 Introduction 
1.1 Protein Kinases 
1.1.1 Protein phosphorylation 
The first description of a phosphorylated protein dates back to the beginning of the 20th 
century. In 1932, a phosphorylated serine was identified in vitellin, a protein from the egg 
yolk.1 Twenty years later, in 1954, the first enzymatic phosphorylation of proteins was shown 
at the example of phosphorylated casein.2 Edwin Krebs and Edmond Fisher revealed that 
phosphorylation of glycogen phosphorylase b is necessary for its activation the following 
year.3 It was the first proof that protein phosphorylation alters target protein activity. Back in 
those days, Krebs and Fisher could not even imagine that they brought to light one of the 
most fundamental regulatory mechanisms in living cells.4 However, both scientists were 
awarded the Nobel Prize in Physiology and Medicine for their research in 1992. Today, it is 
generally accepted that “protein phosphorylation regulates most aspects of cell life, whereas 
abnormal phosphorylation is a cause or consequence of disease”.5 
Protein phosphorylation is a post-translational modification of proteins. Thereby, a phosphate 
group is covalently bound to an amino acid residue. Nucleoside triphosphates, mostly ATP, 
serve as phosphate donors. The -phosphate group from ATP is transferred to the target 
protein. The transferases that catalyze this reaction are called protein kinases. Protein 
phosphorylation is a reversible modification. The enzymes that reverse the reaction are 
protein phosphatases. Phosphatases cleave the covalent bond of phosphomonoesters and 
remove the phosphate groups from proteins.  
Introduction of a negatively charged phosphate group can have dramatic effects on the 
function and activity of the affected protein. One possible consequence of the 
phosphorylation is the structural rearrangement of the target.6–9 Furthermore, 
phosphorylated amino acid residues often function as specific binding sites for other 
proteins.8, 10 Different phosphoresidue binding domains have been identified. For example, 
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phosphorylated tyrosines are specifically recognized by the Src homology 2 (SH2) 
domains.11, 12 14-3-3 proteins bind to phosphorylated serine13, 14 and Forkhead-associated 
(FHA) domains dock to phosphothreonine.15 Protein phosphorylation often constitutes a 
starting point for downstream protein interactions. Generally, phosphorylation might affect 
physico-chemical properties, dynamics, subcellular localization, function, and activity of the 
modified protein.8, 9  
The importance of the post-translational modification is underlined by the fact that the 
majority of proteins in a human cell are phosphorylated at least during mitosis.16 Protein 
phosphorylation plays a crucial role in almost all cellular processes.17, 4 Apart from the 
regulation of intracellular signal transduction, protein phosphorylation is important for 
intercellular communication in the majority of physiological processes.18 Meanwhile, there 
are more than two hundred thousand scientific articles listed by PubMed that deal with this 
topic (last updated on January 2017). It is obvious that such a key process like protein 
phosphorylation should be precisely regulated. Otherwise, severe consequences for the 
affected cells and the whole organism may occur. 
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1.1.2 Kinases in the human genome 
The entirety of kinases in a genome is called kinome. The human kinome was fully 
complemented by Gerard Manning and co-workers in 2002.18 518 protein kinases encoded in 
the human genome were revealed. This constitutes almost 2% of protein coding genes in 
human.18 Protein kinases thereby belong to one of the largest protein families.18, 19 Biological 
significance of protein kinases is reflected by evolutionary conservation of these enzymes. 
Thus, for instance, 80% of protein kinases in C. elegans have homologs in the human 
kinome.20 The common eukaryotic protein kinase catalytic domain is highly conserved.20, 21 
Protein kinases can be classified due to the acceptor amino acid of the substrate protein. 
According to this approach, five groups can be distinguished: serine/threonine protein 
kinases, tyrosine protein kinases, histidine protein kinases, cysteine protein kinases, and 
aspartyl/glutamyl protein kinases.22 The vast majority of protein kinases in eukaryotes are 
either serine/threonine or tyrosine kinases.21 However, there are also so-called “dual-
specificity protein kinases” that can phosphorylate both tyrosine and serine/threonine 
residues.23, 24 
Another approach is to classify the eukaryotic kinases by sequence similarities in their 
catalytic domains.18 Seven major groups can be differenced: AGC, CAMK, CMGC, CK1, STE, 
TKL, and TK kinases.25 Moreover, several families of atypical kinases were identified. These 
enzymes have catalytic activity but lack sequence similarity to the conserved protein kinase 
domain.18 Phylogenetic relations between human protein kinases can be visualized on the 
human kinome tree (Figure 1).18 
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Figure 1: Phylogenetic tree of the human kinome. Seven major protein kinase groups can be distinguished: TKL, 
STE, CK1, AGC, CAMK, CMGC and TK. Kinases discussed more in this work are labeled with bold red letters. The 
phylogenetic tree is adapted from cell signaling technology.
26
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1.1.3 Kinases as pharmacological targets  
Due to the crucial role of protein phosphorylation for the regulation of cellular processes, 
protein kinases became one of the most important drug targets in the twenty-first 
century.5, 27–29 Some studies predict that kinases account for the major part of the 
“druggable” genome.30 
The main indication for targeting protein kinases are oncological malignancies nowadays. The 
initial link between dysregulation of kinase function and cancer development was established 
by the end of the 1970s.10, 28 Back then, it was demonstrated that the viral oncogene v-SRC 
possessed tyrosine kinase activity.31, 32 Meanwhile, significance of kinase signaling is 
demonstrated for a variety of cancer diseases.5, 33–35 Moreover, dependence of some cancer 
cells on mutated or overexpressed kinases could be proved. This phenomenon was called 
“oncogene addiction”.36 This dependence applies both for serine/threonine37 and tyrosine 
kinases.38 
The findings described above led to a novel approach of inhibiting mutated or overexpressed 
kinases in the hope of selective cancer treatment. This was the birth of the “targeted” cancer 
therapy. The idea is to target only the mutated malignant tumours but not all proliferating 
cells as it is the case in the standard chemotherapy. Fewer side effects and better drug 
tolerance are expected by this targeted approach.39 
Cancer, however, is not the only possible indication for targeting protein kinases. There are 
several recent rudiments to inhibit kinase signaling for the treatment of inflammatory 
diseases.27 Tofacitinib, for example, is a JAK inhibitor which was approved 2012 for the 
therapy of rheumatoid arthritis.40 Moreover, directed modulation of protein kinase activity 
could be used in many other maladies such as diabetes.41, 42 Therefore, different kinase 
inhibitors are undergoing clinical studies in inflammatory, neurodegenerative, cardiovascular, 
and metabolic diseases.35  
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1.1.4 Kinase domain structure 
For understanding the binding characteristics of different kinase inhibitors, it is necessary to 
describe the structure of the kinase domain at first. 
The vast majority of protein kinases, 478 of 518,43 possess a very conserved catalytic domain. 
This kinase domain counts about 250 amino acid residues and its structure has already been 
described in essence in 1991 when the structure of PKA was revealed by crystallography.44 
The catalytic kinase domain consists of two lobes, the N- and C-termini. Both lobes are 
connected through a flexible hinge region (Figure 2). 
 
Figure 2: Schematic presentation of the kinase domain of VEGFR-2 (PDB code: 3B8R).
45
 This and subsequent 
figures showing 3D protein structures were visualized using Maestro 10.4.
46
 The N-terminus is colored purple 
and the C-terminus is blue. The hinge region is depicted in green. 
The N-lobe is mainly composed of five antiparallel -sheets, the C-helix and the glycine-rich 
G-loop. The C-helix is crucial for the catalytic activity: a conserved glutamate residue in this 
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helix forms a salt bridge to also conserved lysine (Glu69 and Lys52 in Figure 3). The latter 
interacts with the phosphate groups of ATP. The G-loop, sometimes also referred to as P-
loop, is also important for the interaction with ATP. This loop contains a characteristic glycine 
rich motif and is highly flexible.28 Simplified, it could be said that the N-lobe is rather 
responsible for the ATP orientation and thus activation.  
The C-lobe (marked blue in Figure 2) consists primarily of -helices which are connected by 
numerous loops. One of these loops is the so-called “A-loop”. The A-loop is also referred to as 
the “activation loop”. This flexible region starts with the conserved amino acid sequence: 
aspartate, phenylalanine, glycine and is known as the “DFG motif” (Figure 2).47, 48 Another 
conserved region in the A-loop is the “APE motif” which is comprised of alanine, proline, and 
glutamate.49  
The hinge region (green in Figure 2) flanks the ATP-binding site situated in the cleft between 
both lobes. The binding site can be divided into five distinct regions according to the model of 
Traxler and Furet (Figure 3).50 The adenine residue of ATP is located in the adenine pocket 
(AP) and forms two H-bonds to the hinge region (Asp104 and Met106 in Figure 3). The ribose 
and phosphate residues are placed in the sugar pocket (SP) and in the phosphate binding 
region (PBR), accordingly. Adjacent to the AP, two hydrophobic pockets can be highlighted: 
the hydrophobic pocket I (HP I) that is separated from AP by a “gatekeeper” residue (Gln103 
in Figure 3) and the hydrophobic region II (HR II) which is solvent exposed.43 Both 
hydrophobic pockets are unoccupied by ATP but play a key role in the design of kinase 
inhibitors.51 The gatekeeper residue varies between distinct kinases and this can be used for 
the development of selective inhibitors that address the HP I.48 On the other hand, mutations 
in the gatekeeper residue can cause acquired resistance to kinase inhibitors.52, 53 
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Figure 3: Schematic model of the ATP-binding site in an active kinase. The representation is based on the 
crystallized structure of ERK2 kinase in complex with ATP (PDB code: 4GT3).
54
 Amino acid residue glutamine 103 
(Glu103) was indicated as the gatekeeper in accordance to previous studies.
55
 The pharmacophore model by 
Traxler and Furet was applied.
43, 50
 Maestro 10.4 was used for visualization.
46
 Only key residues are shown for 
better clarity. ATP is depicted with ball and sticks. The amino acid residues are represented as thin tubes. 
H-Bonds are indicated by yellow dashed lines. HR II = hydrophobic region II, AP = adenine pocket, HP I = 
hydrophobic pocket I, SP = sugar pocket, PBR = phosphate binding region.  
The A-loop is inevitable for the catalytic kinase activity. The aspartate in the DFG motif 
chelates the magnesium ion involved in coordinating ATP.49 The same aspartate is also crucial 
for the transfer of the -phosphate from ATP to the target protein.56 The activation loop can 
adopt two different conformations: the DFG-in conformation in the catalytic active state and 
the DFG-out conformation in inactive-like kinase.28 In the DFG-in conformation the aspartate 
residue interacts with the magnesium cation, the adjacent phenylalanine points away from 
the adenine pocket. The ATP-binding site is now accessible for the nucleoside (Figure 4A).57 
On the contrary, in the DFG-out conformation the phenylalanine residue “flips” into the 
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catalytic cleft and obstructs access to the ATP-binding site (Figure 4B). In exchange, the so-
called “deep” pocket becomes available (red oval in Figure 4B). The switch between DFG-out 
and DFG-in conformations is crucial for kinase activation and is strictly regulated by different 
mechanisms, such as phosphorylation of the A-loop.58 
  
(A) (B) 
Figure 4: Binding site in the VEGFR-2 kinase domain in different DFG conformations.
59
 The representations 
were visualized using Maestro 10.4
46
 and are according to the noted PDB codes. (A) DFG-in conformation is 
shown (PDB code: 3B8R).
45
 The phenylalanine residue Phe1047 blocks the deep pocket. The adenine pocket is 
exposable for ATP (blue oval). (B) DFG-out conformation is depicted (PDB code: 3EWH).
60
 The phenylalanine 
residue Phe1047 is now rearranged and blocks access to the adenine pocket for ATP. The deep pocket (red oval) 
can now be addressed by inhibitors. 
Another attribute of the active kinase conformation is the “regulatory spine”.28, 35, 61, 62 This 
spine extends through both kinase lobes, is near-linear arranged, and consists of four 
hydrophobic residues that interact through H-bonds, CH–π-, and hydrophobic 
interactions.61, 35 Distortion of this linear regulatory spine leads to an inactive enzyme 
conformation. Furthermore, there is a second characteristic spine in active kinases: the 
“catalytic spine”.62 The latter crosses both lobes and contains the adenine ring from ATP 
(Figure 5). 
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Figure 5: The regulatory (purple) and catalytic (yellow) spines in the active PKA kinase.
28
 The presentation is in 
accordance to Kornev et al.
62
 and is based on the PDB code: 1ATP.
63
 Disruption of these spines drives the 
inactive kinase conformation. 
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1.2 Protein Kinase Inhibitors 
1.2.1 Progress in the development of potent and selective kinase inhibitors 
In virtue of clear evidence for the significance of protein phosphorylation in pathogenesis 
(compare Chapters 1.1.1 and 1.1.3) there has been a great aspiration to develop potent and 
selective kinase inhibitors since 1970s. The first described protein kinase inhibitors were 
isoquinolinesulfonamides developed in 1984.5, 64 Two years later, in 1986, the antifungal 
compound staurosporine was discovered as a nanomolar inhibitor of PKC.65, 66 The problem 
about the first kinase inhibitors was their lack of selectivity. The highly conserved ATP binding 
pocket and high intracellular ATP concentrations in the millimolar range led to the 
assumption that the development of selective and potent protein kinase inhibitors would be 
an impossible task.5, 39 However, this hypothesis could be impressively disproved by the end 
of 1980s. 
In 1988, first potent inhibitors of tyrosine kinase EGFR have been developed. These 
compounds exposed significant selectivity over serine/threonine kinases and some other 
tyrosine kinases such as the insulin receptor.67 The first clinically approved protein kinase 
inhibitor was rapamycin in 1999.68 Rapamycin is produced by a soil bacterium Streptomyces 
hygroscopicus and had originally been identified as an antifungal compound back in 1970s.69 
Some twenty years later, it was revealed that the intracellular target of rapamycin is a 
serine/threonine kinase. This kinase was then called “mammalian target of rapamycin, 
mTOR”.70 Rapamycin, also known as sirolimus, is still used as immunosuppressive agent for 
prevention of organ transplant rejections. The trade name of rapamycin is Rapamune®.71 
Motivated by the success of rapamycin many research programs were launched for the 
rational design of potent protein kinase inhibitors. A new milestone in this development was 
the approval of imatinib, trade name Gleevec®, in 2001. Imatinib is a potent inhibitor of the 
tyrosine kinase BCR-ABL, an oncogenic fusion protein caused by the Philadelphia 
chromosome.72, 73 Imatinib exhibits antiproliferative effects on the BCR-ABL positive cancer 
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cells and is approved for the treatment of chronic myeloid leukemia (CML) and several other 
malignancies.74 
 
Figure 6: Chemical structure of imatinib, the first approved kinase inhibitor for cancer treatment.  
Today, 35 different small-molecule kinase inhibitors are approved for clinical usage, as by 
October 2016.35 The majority of these drugs are anticancer agents. There are only few 
exceptions: fasudil, a potent ROCK inhibitor, has been approved in Japan for the treatment of 
cardiovascular diseases.75 Tofacitinib, an inhibitor of JAK tyrosine kinase, was approved for 
the therapy of rheumatoid arthritis in 2012.76 Another example of a kinase inhibitor with an 
indication outside of oncology is nintedanib which was approved 2014 for the treatment of 
idiopathic pulmonary fibrosis.77 However, a lot of other indications are in focus of kinase 
inhibitor research. Protein kinase inhibitors are in development for the treatment of 
inflammatory, autoimmune, and neurodegenerative diseases, for instance.27, 78 
The clinical significance of kinase inhibitors is underscored by a great number of these agents 
currently being in clinical trials.35 Furthermore, kinase inhibition is considered to be the 
predominant mode of action of experimental agents at least in cancer research.79 
  
CHAPTER 1  INTRODUCTION 
13 
1.2.2 Classification of protein kinase inhibitors 
Protein kinase inhibitors can be categorized into different types according to their binding 
mode in the target protein. Several classification systems have been proposed. In general, 
three major strategies targeting protein kinases can be highlighted: kinase inhibitors that bind 
to the active DFG-in kinase conformation (type I), inhibitors that target the inactive DFG-out 
state (type II), and the allosteric inhibitors.80, 81 
Recently, a comprehensive system for classification of protein kinase inhibitors has been 
suggested by Roskoski.82 Six different inhibitor types are distinguished. The classification is 
based on the structural properties of the correspondent enzyme inhibitor complexes and will 
be used in the present work. 
Type I inhibitors bind to the active kinase state. The DFG motif is in the in-conformation and 
the regulatory spine is linearly arranged (compare chapter 1.1.4 for structural details of 
kinase domain). Type I½ inhibitors target also the DFG-in conformation, but the regulatory 
spine is distorted now. Therefore, inhibitors of types I and I½ are also called “DFG-in 
inhibitors”. Type II inhibitors bind the inactive DFG-out conformation and can be declared as 
“DFG-out inhibitors”. Both, DFG-in and DFG-out inhibitors are ATP-competitive because they 
target the ATP-binding pocket of the enzymes. Type III inhibitors are allosteric and bind next 
to the ATP site. Type IV inhibitors are allosteric inhibitors too, but target regions distal from 
the catalytic cleft. Allosteric inhibitors are considered to be more selective than the 
compounds that target directly the ATP-binding site.83 Inhibitors that span two regions of the 
kinase domain are labelled as Type V inhibitors. Type VI inhibitors bind covalently to the 
target kinase and are irreversible, on the contrary to the Type I-V inhibitors.82 
The majority of the approved protein kinase inhibitors are the DFG-in inhibitors, such as the 
BRAFV600E inhibitors vemurafenib and dabrafenib.81, 84 The most prominent example for a DFG-
out inhibitor is imatinib. Trametinib is an example of an allosteric kinase inhibitor of type III.82 
Type VI inhibitors form a covalent bond to cysteine residue in the target kinase via Michael 
addition. Examples for approved covalent inhibitors are ibrutinib and afatinib, both tyrosine 
kinase inhibitors. 
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1.2.3 Comparison of DFG-in and DFG-out inhibitors 
As mentioned above both DFG-in and DFG-out inhibitors target the ATP-binding pocket in the 
catalytic cleft of kinases.35 DFG-in inhibitors use heterocyclic systems to occupy the adenine 
pocket and form H-bonds to the hinge region57, 80 (compare Figure 3). Due to the high 
conservation of adenine pocket, the less conserved adjacent hydrophobic pocket I (HP I) and 
the hydrophobic region II (HR II) should be addressed to increase selectivity. Especially the 
gatekeeper amino acid plays an important role for the design of DFG-in inhibitors. 
DFG-out inhibitors address additionally to the adenine pocket also the deep pocket and the 
adjacent regions HP I and HR II. The deep pocket is accessible only in the DFG-out kinase 
conformation (compare Figure 4). DFG-out inhibitors are often larger than their DFG-in 
counterparts. 
DFG-out kinase conformations are structurally more diverse than DFG-in states.81 Moreover, 
the deep pocket is far less conserved compared with the ATP-binding pocket offering specific 
interaction points for the design of selective inhibitors.85, 86 Therefore, DFG-out inhibitors are 
in general considered to be more selective than Type I or Type I½ inhibitors.83, 85, 87–90 
However, there are some reports about promiscuousness of DFG-out inhibitors.84 Imatinib, 
for example, binds as DFG-out inhibitor not only the ABL kinase domain but also other 
tyrosine kinases: c-Kit and PDGFR. Summarizing, targeting the DFG-out conformation by Type 
II inhibitors does not guarantee high selectivity per se.81 Furthermore, there are several 
demonstrated examples of selective DFG-in inhibitors.91–93 In conclusion, the unique 
structural properties of the respective target kinase should be utilized for the design of highly 
selective protein kinase inhibitors.81 
Beside the selectivity, other pharmacological properties of kinase inhibitors should be taken 
in consideration when comparing DFG-in and DFG-out inhibitors. All DFG-in inhibitors must 
compete with high intracellular ATP concentrations in the millimolar range which can 
contribute to unfavorable loss of potency in vivo. In contrast to some former references,87 
nowadays, DFG-out inhibitors are considered to be ATP-competitive too, since inactive DFG-
out kinases can still bind ATP.82, 35 Nevertheless, kinases have different KM values for ATP 
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depending on whether they are in active conformation or not.94 The cellular potency of a 
Type II inhibitor depends therefore on the kinase KM value in the inactive state.
35 
The physiological response to a drug in vivo depends not only on its selectivity but although 
on the amount of inhibitor bound to the target enzyme over time. DFG-out inhibitors have 
been repeatedly reported to have extended target residence time and this might be beneficial 
for pharmacological applications.83, 95  
Another important issue to consider when comparing DFG-in and -out inhibitors are different 
physiological effects that can be obtained by their application.84 An example is the inhibition 
of the BRAF serine/threonine kinase. Mutations in BRAF kinase domain are found in a variety 
of cancers.96 The BRAFV600E mutation determines a constitutively active kinase allowing 
activation of MEK/ERK signaling in tumor cells in the absence of any extracellular stimuli.97 
This gain-of-function mutation stabilizes the active DFG-in conformation.98 On the contrary, 
the wild-type BRAF adopts the DFG-out conformation in the absence of extracellular signals.98 
This discrepancy in conformational states is exploited by selective BRAFV600E inhibitors 
vemurafenib and dabrafenib.99–101 Both vemurafenib and dabrafenib are DFG-in inhibitors. On 
the contrary, type II inhibitors, e.g. sorafenib, bind to the DFG-out conformation of BRAF 
kinase and exhibit no selectivity towards the V600E-mutant.102 Therefore, DFG-in inhibitors 
appear to be more preferable for targeting the BRAFV600E oncogenic kinase. In summary, every 
individual (patho)physiological situation should be carefully examined to decide which type of 
inhibitor is more advantageous for the special circumstances.84  
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1.2.4 Benefits and drawbacks of protein kinase inhibitors in clinical 
applications 
Undoubtedly, protein kinase inhibitors revolutionized cancer treatment over the last fifteen 
years. Small molecule kinase inhibitors (smKIs) are ranked among so-called “targeted 
therapy”.103–105 In contrast to conventional chemotherapy which combats all rapidly 
proliferating cells in an organism, kinase inhibitors take effect by specifically targeting 
particular cellular processes involved in the pathogenesis. The approach of inhibiting 
oncogenic kinases for therapeutic applications was impressively proved by imatinib treatment 
of CML. Enormous efforts to develop novel potent kinase inhibitors culminated in the 
approval of more than 30 substances by the end of 2016. This is a remarkable achievement in 
the history of pharmaceutical research.48 Today, protein kinase inhibitors are widely used in 
the treatment of a variety of tumors and display a significant clinical advantage for affected 
patients compared to prior therapies in many cases.105 Imatinib treatment, for instance, 
produces a durable response with a survival rate over 85% for eight years.106  
However, apart from all progress and achievements in the development of protein kinase 
inhibitors a lot of remaining problems should be addressed. Even though kinase inhibitors are 
generally less toxic than highly dosed chemotherapy, therapy with smKIs can cause severe 
side effects.107–109 For example, cardiac- and skin-related toxicities are common for many 
kinase inhibitors.35 Often, undesired adverse effects can be attributed to off-target 
interactions due to poor selectivity of applied inhibitors. Nevertheless, even inhibition of the 
desired target kinase can lead to compound toxicology. The cardiotoxicity of imatinib, for 
example, is caused by inhibition of the ABL kinase which is also important for appropriate 
cardiomyocyte function.110 
The most important drawback in therapy with kinase inhibitors is probably the development 
of resistances.35, 48, 81, 105 For instance, most patients with melanoma who initially respond to 
vemurafenib treatment relapse within a year.98, 111, 112 Many different mechanisms for the 
manifestation of acquired resistance to smKI treatment are explicitly reviewed.35, 48, 105 It is 
not within the framework of the present thesis to reveal these mechanisms in greater detail. 
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Roughly, a distinction can be made between the “on-target” resistances such as point 
mutations of the gatekeeper residue or amplifications of the targeted kinase, and the “off-
target” resistances such as upregulation of downstream or parallel signaling pathways and 
modulation of cellular metabolism or efflux of the inhibitor.57, 105, 113–115 The cancer cells 
become tolerant to kinase inhibitors due to selection pressure. This evolution is based on the 
high genomic instability of tumors.116, 117 
Rational strategy to overcome acquired therapeutic resistance remains one of the most 
important challenges for future development of smKIs. Therefore, precise understanding of 
resistance mechanisms in each individual patient appears to be a necessary prerequisite for 
further progress. In this context, genomic screening of resistant tumor samples is important 
for the personalized therapy. 
Today, several different approaches are utilized to combat acquired resistances. When 
dealing with “on-target” mutations it is rational to develop second-line inhibitors that still 
target the mutated kinase. For example, two second-generation BCR-ABL inhibitors, dasatinib 
and nilotinib, are available for the treatment of imatinib-resistant CML patients.118 
Resistances caused by reactivation of downstream or parallel signaling cascades might be 
tackled by a combination of two or even more inhibitors. The combination therapy with 
BRAFV600E inhibitor dabrafenib and MEK inhibitor trametinib delays the occurrence of drug 
resistance in the melanoma treatment compared with the single agent treatment.119 
Unfortunately, the majority of patients acquire resistances even to these second-line 
therapies.120 An interesting approach is the intermittent dosing of kinase inhibitors to 
forestall the arising of resistances.121 This strategy is based on the notion that resistant cancer 
cells might be drug-dependent.122 Some ongoing clinical studies are investigating possible 
benefits of intermittent dosing schedules.123, 124 
Besides preventing resistances, efforts for minimization of side effects are required. 
Increasing the selectivity of administrated kinase inhibitors appears to be the method of 
choice to minimize undesired toxicology. Highly selective inhibitors would be valuable tools to 
elucidate certain functions of a particular kinase in vitro. Moreover, selective inhibitors should 
be used when integrating different compounds in combination therapies. However, it has 
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become clear that absolute selectivity is not necessarily required for successful clinical 
application.48 The maybe most prolific inhibitor hitherto, imatinib, is quite promiscuous and 
targets apart from BCR-ABL some other tyrosine kinases such as PDFGR and KIT.125 There are 
several other examples where multitarget selectivity might be more suitable for cancer 
treatment.35, 48 Nevertheless selectivity profiling should be a must prior to clinical 
applications. Therefore, efficient kinase selectivity assays over the whole kinome are 
required. Particularly, novel assays for allosteric inhibition are needed.57, 86 
Another shortage that should be improved is the fact that the majority of developed kinase 
inhibitors target only a small subset of the kinome.48 More kinases and their role in 
pathogenesis should be better explored. This might lead to a greater variety of kinase 
inhibitors approved for many more applications additional to oncology. 
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1.3 Caged kinase inhibitors 
1.3.1 Regulation of biological processes by light 
Exact spatiotemporal control of biological processes is of great significance both for basic 
research and clinical applications. Light represents an ideal external trigger that can be 
precisely adjusted in terms of intensity, temporal and local resolution.126 It offers numerous 
advantages for the regulation of biological processes:126–130 Light is non-invasive and exhibits 
great orthogonality toward most chemical and biological systems. By means of modern light 
sources, such as lasers or LEDs, important characteristics like wavelength, intensity, resolution 
and duration of illumination can be accurately regulated.130  
The idea to exploit the positive characteristics of light for clinical applications is not new. First 
medical applications were developed by the end of 1970s as the PUVA therapy had been 
approved. PUVA stands for “psoralen and ultraviolet A” and is used for the treatment of skin 
diseases such as psoriasis, vitiligo and eczema.131, 132 Thereby, psoralen is applied to sensitize 
the skin prior to irradiation.  
Another example of a successful application of light in medicine is the photodynamic therapy 
(PDT).133–135 In PDT photosensitizers are utilized to generate singlet oxygen (1O2) in living 
tissue when irradiated with light.127, 136 Singlet oxygen is a reactive oxygen species (ROS) 
which is cell toxic. PDT is used for the treatment of cancer and infectious diseases.137–139 
Both PUVA and PDT do not affect selective molecular targets but cause nonspecifically 
damage in irradiated tissue. However, several novel approaches to apply light more 
selectively have been developed during the past three decades. Today, three major principles 
for the regulation of biological process with light can be distinguished:140 Irreversible 
photo(de)activation, reversible photoswitching and optogenetics. 
Irreversible photoactivation exploits so called “caged compounds”. The term “caging” was 
coined by Kaplan et al. who attached photoremovable protecting groups to ATP and utilized 
this “caged ATP” to study the Na+/K+ pump in 1978.141 Today, the term “caged” is established 
for “biologically active compound that has been inactivated with a photolabile protecting 
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group” (PPG).126 Synonyms to “caged” are “photoactivatable” and “light-triggered”.140 When 
irradiated by light with appropriate wavelength and intensity the photolabile group is cleaved 
and the active molecule is released. The process of uncaging is irreversible. The mechanism of 
irreversible photoactivation is shown schematically in Figure 7. 
 
Figure 7: Schematic representation of irreversible photoactivation (uncaging). A photoremovable protecting 
group (PPG, purple star in the figure) is covalently bound to a compound (blue triangle). As a consequence, the 
compound is caged and inactive. After irradiation with light at appropriate wavelength the PPG is cleaved and 
the released active compound can bind to its target. Thus, biological effects can be induced upon irradiation. The 
activation is irreversible. Some graphical elements used in the visualization such as membrane and receptor 
were adopted from Servier Medical Art.
142
 
The irreversibility of uncaging is an inherent disadvantage of the concept. Another drawback 
of irreversible photoactivation is the formation of a by-product: the cleavage product of the 
PPG.126, 130 This by-product can exhibit undesired biological effects. Moreover, the cleaved 
PPG might interfere with the photoreaction by absorbance of used light. However, caging 
approach offers some advantages too: because of the irreversibility, there is no steady state 
and excellent off/on ratios can be achieved.130 Furthermore, insertion of a PPG can 
completely abolish the biological effect of a compound. The possible toxicity of the cleaved 
PPG might also be useful in terms of fighting tumor tissue synergistically. 
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Reversible photoswitching utilizes the principle of photochromism: Two different forms of a 
chemical species can be reversibly transformed into each other by the absorption of 
electromagnetic radiation.143 For biological applications a photoswitchable element is usually 
inserted into the molecular structure of a bioactive compound.127 An inactive substance can 
be shifted to the active isomer by means of light irradiation. The reaction can be inverted by 
illumination at a different wavelength.126, 127, 130, 140, 144 The concept enables a dynamic control 
of a biological effect that can be reversibly turned on and off. The mechanism of the 
reversible photoswitching is schematically depicted in Figure 8. 
 
Figure 8: Schematic representation of reversible photoswitching.
130
 An inactive compound (blue square) can be 
reversibly switched to its active isomer (dark blue triangle) that can interact with its biological target. The 
activation is reversible. The backward reaction can be induced by irradiation at a different wavelength. Some 
graphical elements used in the visualization were adopted from Servier Medical Art.
142
  
The reversibility and the absence of any by-products are undeniable advantages of 
photoswitching in comparison with the photoactivation of caged compounds described 
above. However, occurrence of steady states where both isomers are present can be a non-
negligible intricacy of photoswitching.126 Therefore, high off/on rates are difficult to achieve 
and biological effects are often not completely switched off by irradiation of active 
compounds.126, 140, 145–147 
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Optogenetics is the combination of optical and genetic methods to achieve dynamic control 
over biological events in specific cells or tissues.148, 149 The method relies on the expression of 
genetically encoded photo sensor proteins. Most commonly, the photosensitive proteins 
belong to the rhodopsin family. The function of photoresponsive proteins can be changed 
upon irradiation and a biological effect can be induced, compare Figure 9.  
 
Figure 9: Schematic representation of optogenetics.
130
 A genetically modified, photoresponsive protein, mostly 
an ion channel can be activated by light to evoke a biological effect. Some graphical elements used in the 
visualization were adopted from Servier Medical Art.
142
  
Optogenetics offers unique tools to investigate basic physiological processes, such as 
depolarization of neurons,150 dynamics in neural circuits151 or even sleeping behavior of 
model organisms.152 Optogenetics was decorated as “Nature method of the year 2010”.153 
However, apart from its advantages for fundamental research, necessity of genetic 
manipulation makes this approach unsuitable for medical applications.127 
Within the framework of this work it is impossible to mention all current examples for 
successful implication of light in addressing fundamental biological questions. There are a lot 
of comprehensive reviews dealing with this topic.126–130, 154 Exclusively the concept of kinase 
inhibitor caging will be discussed in more detail in the present work. 
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1.3.2 Caging of protein kinase inhibitors 
The drawbacks of protein kinase inhibitors described in the chapter 1.2.4 explain the search 
for novel approaches in the field of smKIs. Major goals are minimization of systemic side 
effects of kinase inhibitors and prevention of resistances. Spatiotemporal control of kinase 
inhibitor activity might be a valuable strategy to achieve these objectives. Photoactivatable 
caged protein kinase inhibitors enable a precise local control of the inhibitory activity. On the 
supposition that an inactive caged kinase inhibitor shows good bioavailability and is well 
distributed within entire organism, site directed reactivation by light irradiation could possibly 
spare non-irradiated tissues from undesired side effects. Furthermore, a sharp increase of the 
active inhibitor concentration in the target tissue might be achieved by irradiation.128 
Therefore, it might be possible to confront malignant cells with abruptly high concentrations 
of an inhibiting agent. These elevated concentrations would not be feasible on the basis of 
systemic administration due to adverse effects. In other words, photoactivatable kinase 
inhibitors could possibly enable locally restricted high-dosage cancer therapy. Moreover, the 
temporal control of inhibitor release might present a possibility for a potent intermittent 
therapy which could be favorable in prevention of resistances.155, 122, 121 Eventually, caged 
protein kinase inhibitors offer a valuable tool for studying cellular kinase functions and 
signaling pathways. 
The idea to use caged compounds as a technique for investigating biological processes in vitro 
is anything but new. As mentioned above first caged ATP has already been utilized in 1978.141 
Since then, different photoactivatable compounds have been described such as caged 
neurotransmitters, second messengers and phospholipids.156–160 The caging concept has been 
utilized for examination of cellular signaling161, 162 or investigation of embryonal 
development.163–166 The first described photoactivatable protein kinase inhibitor was a 
modified peptide-based inhibitor of PKA.167, 162 However, despite the significance of protein 
phosphorylation for cellular processes, only a few caged smKIs have been reported so 
far.165, 166 Moreover, to the best of my knowledge, there were no reports about caging of 
approved kinase inhibitors at the time of the beginning of my doctoral studies.  
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1.3.3 Photoremovable protecting groups 
The caging concept utilizes photoremovable protecting groups (PPG). Several requirements 
should be fulfilled for biological applications.140, 160, 168 PPGs should be stable as well as soluble 
under physiological conditions.140 They should be easy to introduce and rapidly cleaved upon 
light irradiation. The introduction of a PPG should ideally eradicate the biological activity of 
compounds to be protected. Large molar extinction coefficients  and high quantum yields  
of caged compounds are favorable for fast uncaging.140 The photoinduced reaction should be 
clean and quantitative.160 The active compound should be transparent at the wavelength 
used for decaging to avoid decomposition. The cleavage products of the PPG should also be 
transparent at the irradiation wavelength to avoid competitive absorption of light.168, 160 
Furthermore, the photochemical by-products should not be toxic.160, 140 However, the last 
characteristic is not indisputable. The toxicity of the photoinduced by-products could also be 
advantageous. For example, cytotoxic by-products might be used synergistically with released 
active kinase inhibitors to fight irradiated cancer cells. Another important criterion for the 
selection of a PPG is the wavelength required for the photoinduced cleavage. Generally, high 
energetic irradiation with wavelengths under 300 nm should be avoided because of 
presumable tissue damage.160 Irradiation within the bio-optical window (650 – 850 nm)169–171 
might be most suitable to avoid undesirable absorption by endogenous chromophores, such 
as hemoglobin.172, 173 Penetration depth of wavelengths under 650 nm is quite low, compare 
Figure 10. Therefore, PPGs that can be cleaved with red or near-infrared irradiation (NIR) 
should be most favorable for usage in biological settings. 
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Figure 10: The penetration depth of different light wavelengths into biological tissue.
172, 173
 
To this day, a variety of highly diverse PPGs have been described.140, 160, 168, 174, 175 According to 
Klan et al. six different classes of PPGs can be distiniguished.160, 176 Examples for main 
categories of photoremovable protecting groups can be found in Table 1. 
However, there is no PPG that would perfectly fulfill all characteristics described above.160, 168 
The choice of a particular protecting group should be guided by current experimental settings 
and requirements. 
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Table 1: Non-comprehensive overview of PPGs.
160, 176, 177
 “X” denotes the compounds released upon irradiation. 
Category of PPG Examples of PPG 
Arylcarbonylmethyl 
groups 
 
Nitroaryl groups 
 
Coumarin-4-ylmethyl 
groups 
 
Arylmethyl groups 
 
Metal-containing groups 
 
Miscellaneous groups 
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1.3.4 o-nitrobenzyl derivatives as photoremovable protecting groups 
In course of the present work the o-nitrobenzyl derivatives have been utilized as PPGs for 
caging of active kinase inhibitors. Due to their stability and easy chemical accessibility, these 
protecting groups have been the most commonly used groups for photocaging concept.178 
Originally, the o-nitrobenzyl derivatives were applied as protecting groups in organic 
synthesis.179 The first scientific work with caged compounds utilized these groups already.141 
Many derivatives of o-nitroaryl groups with different physicochemical properties have been 
described for various applications.165, 166, 180–183 Today, a lot of reagents caged with nitroaryl 
groups are commercially available.184 
The mechanism of the photoinduced cleavage of a o-nitrobenzyl PPG has extensively been 
investigated.178, 185, 186 A reaction schema including hydrogen transfer from the o-alkyl 
position to the nitro group, formation of an aci-nitro tautomer and subsequent cyclization to 
a benzisoxazolol derivative is widely accepted.160, 176 In the last step the benzisoxazolol 
derivative is deprotonated and the PPG is released as o-nitrosobenzyl derivative. The 
deprotection mechanism of a o-nitrobenzyl group is schematically shown in Figure 11.  
Several parameters determine the reaction rate of the photoinduced deprotection: The caged 
compound “X”, the substitution pattern of the nitrobenzylic ring, the solvent and its 
pH.168, 178, 181 The released nitroso by-product, cleavage product of the PPG, is cell toxic.168 
Nevertheless, this toxicity could be used for some application as has already been discussed 
above. 
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Figure 11: Schematic representation of release mechanism of o-nitrobenzyl caged compounds.
176, 178, 185, 186
 “X” 
stands for the released compound.  
To increase the wavelength necessary for the photoinduced cleavage of an o-nitrobenzyl PPG, 
the nitroaryl ring can be substituted with methoxy groups.187 The 4,5-dimethoxy-2-
nitrobenzyl (DMNB) group can be released upon irradiation at about 350 nm (for chemical 
structure see Table 1). This PPG was utilized in the present work for caging the active smKIs. 
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2 Scope 
The current thesis is devoted to two topics. The main focus of the work was on the biological 
characterization of novel photoactivatable “caged” prodrugs of protein kinase inhibitors. The 
aim of this project was to develop caged prodrugs of approved protein kinase inhibitors and 
to evince their applicability as valuable pharmaceutical tools in vitro. It was supposed that 
light irradiation of caged inhibitors enables a spatiotemporal control over kinase inhibition. To 
prove this hypothesis, extensive biological characterization of photoactivatable compounds 
should have been performed. For this purpose, novel assay techniques including custom-
made light sources had to be evaluated. 
Design and characterization of photoactivatable protein kinase inhibitors was conducted 
following the workflow shown in Figure 12.  
 
Figure 12: Workflow for the caging of protein kinase inhibitors.
176
 
Starting point was the selection of active inhibitors with validated molecular targets. Several 
potent protein kinase inhibitors including approved agents such as imatinib,188, 189 
vemurafenib,99, 100 and dabrafenib101 have been chosen as model compounds. Furthermore, 
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3,4-diarylmaleimides190, 191 as VEGFR-2 inhibitors have been investigated for their applicability 
to this technique. VEGFR-2 (vascular endothelial growth factor receptor) is a receptor tyrosine 
kinase (RTK) and plays an important role in the regulation of angiogenesis.192  
An essential prerequisite for the caging concept is UV-stability of the parent compound. This 
stability was to be verified for all of the deployed inhibitors. Photostable smKIs were to be 
examined for possible pharmacophore sites. Molecular modeling was used to predict key 
interactions between inhibitors and corresponding target kinases. 
Caged kinase inhibitors were to be synthesized by coupling the active compounds with an 
appropriate PPG. Thereby, previously determined key pharmacophore sites were to be 
addressed. In order to identify an optimal wavelength for irreversible cleavage of the coupled 
PPG, photochemical characterization of caged inhibitors had to be performed. It was assumed 
that a rapid release of the parent inhibitor upon irradiation is necessary for successful 
biological applications. To describe the kinetics of the photoinduced release, irradiation 
studies of caged inhibitors in different solvents had to be conducted. 
Subsequent biological characterization of caged smKIs in vitro had two objectives. The first 
aim was to demonstrate the loss of cellular activity of caged inhibitors. The second goal was 
the proof of principle: it should be demonstrated that the irradiation at an appropriate 
wavelength could reactivate the respective kinase inhibitors. The photoinduced release of the 
parent compound should be controlled both temporally and locally. Several in vitro test 
systems such as proliferation assays, western blot analyses and immunostaining were utilized 
for validation of this spatiotemporal steering. Moreover, these assays had to be optimized for 
both dark conditions and directed irradiation.  
Furthermore, additional questions not depicted in the workflow (Figure 12) were to be 
addressed. First, possible cellular toxicity of the cleaved PPG should be investigated. Second, 
the interference of the applied UV light with the test assays was to be examined. The ultimate 
aim of the whole project was a launch of animal models for testing the caged inhibitors. 
However, it should be said that in vivo characterization was not the focus of the present work. 
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Application of the caging concept on smKIs is a multidisciplinary approach. The main focus of 
my research in this work was the biological characterization of protein kinase inhibitors. The 
synthesis of the caged compounds was performed by my kind colleagues: Dr. Rebecca 
Horbert (vemurafenib176, 193 and maleimide176, 194 projects) and Dr. Melanie Zindler (imatinib 
project195). Thorsten von Drathen contributed to chemical analysis in the dabrafenib 
project.196, 197 
The second topic the current work deals with is the characterization of novel DFG-in and 
DFG-out PDGFRinhibitors. PDGFR stands for platelet-derived growth factor receptor and is 
also a RTK. PDGFR exhibits a significant importance for several cellular transduction pathways 
regulating cellular proliferation, differentiation and tumor progression.198, 199 Both RTKs 
VEGFR-2 and PDGFR are numbered among the major targets for development of effective 
inhibitors in oncology.200 Potent DFG-in and DFG-out inhibitors of PDGFR with the same 
chemotype were to be developed and characterized in vitro. Pyrazine-2-one scaffold derived 
from marine hamacanthins served as a lead structure. Structure-activity relationships (SAR) of 
different pyrazine-2(1H)-one derivatives were to be examined.201 Further hit optimization was 
to be performed applying molecular modeling studies such as prediction of water 
thermodynamics.202 The ultimate aim of the project was the comparison of potent DFG-in and 
DFG-out inhibitors with the same chemotype (Figure 13) regarding their selectivity and 
potency in cellular assays.203 The chemical basis for the biological characterization was laid by 
previous works of Dr. Joachim Schlosser204 and Dr. Eugen Bethke (born Johannes).205
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Figure 13: Hamacanthin B as lead for the development of PDGFRinhibitors with pyrazine-2(1H)-one scaffold. 
Comparison between DFG-in inhibitors 1 and 2 and DFG out inhibitor 3 was one of the aims in the present thesis. 
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3 Results and Discussion 
The current work is a cumulative dissertation. The thesis consists of seven peer-reviewed 
scientific papers that were prepared during my PhD work. Each publication is shortly 
introduced and then reproduced as published in corresponding journals. Supplementary 
information (SI) for each paper is included. Furthermore, some additional data not included in 
publication is provided after the corresponding paper (as is the case with photoactivatable 
prodrugs of vemurafenib). 
The first four papers address the topic of photoactivatable “caged” protein kinase inhibitors. 
The last three publications deal with the development of potent DFG-in and DFG-out PDGFR 
inhibitors. 
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3.1 Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib 
Rebecca Horbert,§ Boris Pinchuk,§ Paul Davies, Dario Alessi, and Christian Peifer 
§Rebecca Horbert and Boris Pinchuk contributed equally to this work. 
ACS Chem. Biol. 2015, 10, 2099−2107. 
http://pubs.acs.org/doi/full/10.1021/acschembio.5b00174 
(The article is licensed under the terms of the ACS AuthorChoice license) 
Vemurafenib was the first approved drug for personalized therapy of BRAFV600 mutated 
cancers.98 Since its approval for melanoma therapy in 2011, vemurafenib has shown 
impressive clinical results regarding tumor regression and prolonged survival rates.111, 112, 206 
Unfortunately, most patients develop vemurafenib resistance which cause rapid relapse after 
only several months of therapy.207–209 Furthermore, patients often suffer from side effects 
during the treatment.210, 211 
In the following paper193 novel photoactivatable prodrugs of vemurafenib were described. 
The caged compounds were designed, synthesized and characterized both photochemically 
and in vitro. The workflow for the caging of protein kinase inhibitors (Figure 12) could be 
successfully applied up to animal models. After verification of the UV-stability of vemurafenib, 
several caged derivatives of the inhibitor were synthesized. Therefore, the DMNB group was 
utilized as a PPG. The caged compounds were proved to be inactive in several in vitro assays 
such as kinase assays, western blot analysis, and cell proliferation assays. Photochemical 
characterization revealed an optimal wavelength for deprotection. Release of active 
vemurafenib upon irradiation could be impressively proved in all used cellular assays. 
Different pharmacophore sites of vemurafenib were compared in terms of their applicability 
for caging. Furthermore, cellular toxicity of the cleaved PPG could be measured. This study 
was the first proof of principle that photoactivatable prodrugs of approved smKIs can be 
applied as useful pharmacological tools. 
Dr. Rebecca Horbert synthesized the caged compounds. I performed the characterization in 
vitro such as western blot analysis and cell proliferation assays and wrote the half manuscript. 
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3.1.1 Additional data measured following publication of the article 
“Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib” 
Release of active vemurafenib from its caged prodrugs was proved to be precisely controlled 
by UV irradiation in the paper “Photoactivatable Prodrugs of Antimelanoma Agent 
Vemurafenib”. The inhibitory activity was measured only upon irradiation of caged 
compounds. However, no local resolution of photoinduced release was demonstrated.  
To prove that activity of vemurafenib can be restored spatially, immunofluorescence 
experiments were performed. SKMel13 melanoma cells which carry the BRAFV600E mutation212 
were used. The cells were seeded to give 16,000 cells in 50 μl per well into a 96-half-well 
plate (#675986, Greiner Bio-One GmbH, Kremsmünster, Austria). The plate was incubated for 
48 h at 37 °C in a humidified atmosphere with 5% CO2. Vemurafenib and its photoactivatable 
prodrug 4 (compare Figure 14 for chemical structures) were dissolved in cell medium and 
added to the cells to give the end concentrations of 1 and 5 µM, respectively. 
 
Figure 14: Chemical structures of vemurafenib and its photoactivatable prodrug 4. The caged compound 4 
corresponds to the caged prodrug 2 in the article “Photoactivatable Prodrugs of Antimelanoma Agent 
Vemurafenib”.
193
 
The cells were incubated with the compounds for 1 h at 37 °C and were then fixed with 4% 
paraformaldehyde, washed with DPBS, and permeabilized with ice cold methanol. Afterwards 
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the cells were blocked with 5% goat serum and stained with phospho-Erk rabbit mAb (#4370, 
New England Biolabs GmbH, Frankfurt am Main, Germany). The primary Ab was diluted 1:500 
in Ab dilution buffer (DPBS with 0.3% Triton X-100 and 1% BSA) prior to use. After incubating 
with primary Ab overnight at 4 °C, the cells were washed with DPBS and treated with 
secondary anti-rabbit Ab. The secondary Ab was conjugated with the fluorescent dye Alexa 
Fluor® 594 (#8889, New England Biolabs GmbH, Frankfurt am Main, Germany). The anti-
rabbit Ab was diluted 1:1000 in Ab dilution buffer prior to use. After 2 h incubation at 37 °C in 
the dark, the cells were washed with DPBS and the fluorescence images were taken at the 
ImageXpress® Micro XL (Molecular Devices, Sunnyvale CA, USA). The magnification was 10x. 
Texas red filter set was used for the visualization. The results of this staining without UV 
irradiation are shown in Figure 15. 
As previously described in the publication,193 active vemurafenib blocks the constitutively 
active BRAFV600E kinase. This inhibition causes the reduction of phosphorylated ERK in the 
cells. Therefore, active vemurafenib reduces the signal of phospho-ERK (also compare the 
western blot analysis in the paper).193 On the contrary, the caged prodrug of vemurafenib 4 
should not be active in the dark and should not block the phosphorylation of ERK. This could 
be verified by the immunofluorescence assay (Figure 15). Only vemurafenib diminishes the 
red signal of phosphorylated ERK. By contrast, the caged prodrug is inactive. 
 
Figure 15: Phospho-ERK staining of melanoma SKMel13 cells after incubation with vemurafenib and the 
photoactivatable prodrug 4. The top four rows of a 96-well-plate with treated cells are shown. The 
phosphorylated ERK is immunostained with a combination of primary and secondary Ab. The latter one is 
conjugated to a red fluorescent dye. The experiment was performed in dark without UV irradiation.  
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A variation of the immunofluorescence experiment described above was performed. Herein, 
the SKMel28 cells in four bottom rows of the same 96-well-plate were treated with prodrug 4 
and DMSO as control. On the contrary to top rows, the bottom rows were now irradiated at 
365 nm with 0.9 W for five minutes. Apart from that, the same protocol as for the not 
irradiated wells was applied. The results of this experiment are shown in Figure 16. 
First, it could be demonstrated that the applied irradiation alone did not reduce the 
phosphorylation of ERK. Thus, the irradiated cells treated with DMSO still exhibited strong red 
signal of phospho-ERK (Figure 16). Furthermore, it was shown that the caged prodrug 4 could 
be spatially reactivated by irradiation. The caged compound inhibited the phosphorylation of 
ERK only where irradiated, compare Figures 15 and 16. 
 
Figure 16: Phospho-ERK staining of melanoma SKMel13 cells after incubation with DMSO and the 
photoactivatable prodrug 4 of vemurafenib. The bottom four rows of the same 96-well-plate as in Figure 15 are 
shown. These rows were irradiated at 365 nm with 0.9 W for five minutes. The phosphorylated ERK is 
immunostained with a combination of a primary and a secondary Ab. The latter one is conjugated to a red 
fluorescent dye.  
The demonstrated immunofluorescence experiments proved the possibility of local control of 
action of protein kinase inhibitors in vitro. The photocaged inhibitors can be precisely 
reactivated by spatial resolution of applied irradiation. 
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3.2 Design, Synthesis, and Characterization of a Photoactivatable 
Caged Prodrug of Imatinib 
Melanie Zindler, Boris Pinchuk, Christian Renn, Rebecca Horbert, Alexander Döbber, and 
Christian Peifer 
ChemMedChem 2015, 10, 1335 – 1338. 
DOI: 10.1002/cmdc.201500163 
 
Imatinib (Figure 6) was the first rationally developed protein kinase inhibitor.5 The inhibitor 
targets the ABL kinase and was originally approved for the therapy of Philadelphia 
chromosome positive CML in 2001.188, 189 Afterwards, it was discovered that besides ABL 
imatinib also potently inhibits other tyrosine kinases such as c-Kit and PDGFR.213 Therefore, 
the agent was also approved for the treatment of further cancers including Philadelphia 
chromosome positive ALL214 and gastrointestinal tumors (GIST).215 
In the following paper195 a photoactivatable prodrug of imatinib was described. The goal was 
to develop a pharmacological tool that could be highly useful for studying multiple signaling 
pathways affected by imatinib. Molecular modeling studies were applied to identify suitable 
pharmacophore sites in imatinib for attaching a PPG. Two possible positions were 
determined: the NH functions of the amide in the benzanilide and of the N-arylpyrimidine-2-
amine. The amide function was utilized in the published paper. Two different PPGs were 
attached to this moiety: the DMNB group and the coumarin-4-ylmethyl group (compare 
Table 1). Therefore, two different photoactivatable derivatives of imatinib, compounds 5 and 
6, were yielded: (Figure 17).  
Both caged compounds were photochemically characterized. It became obvious that the 
coumaryl-4-methyl protected derivative 6 was not eligible for biological applications due to 
very slow photoinduced release of imatinib. On the contrary, the DMNB-protected derivative 
5 was successfully utilized as a photoactivatable prodrug of imatinib in a kinase assay. 
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Figure 17: Chemical structures of photoactivatable prodrugs of imatinib.
195
 DMNB- caged imatinib derivative 5 
and coumarin-4-ylmethyl caged derivative 6 correspond to the compounds 2 and 3 in the article “Design, 
Synthesis, and Characterization of a Photoactivatable Caged Prodrug of Imatinib”, respectively.
195
  
Dr. Melanie Zindler synthesized the caged derivatives of imatinib. I performed the kinase 
assays together with Christian Renn who was my Master student at that time.  
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3.3 Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors 
Boris Pinchuk, Rebecca Horbert, Alexander Döbber, Lydia Kuhl and Christian Peifer 
Molecules 2016, 21(5), 570. 
DOI: 10.3390/molecules21050570 
 
The vascular endothelial growth factor receptor 2 (VEGFR-2) is a key mediator of 
angiogenesis.192 This tyrosine kinase plays an important role in tumor growth and intraocular 
diseases and is therefore a significant drug target.216–218 Today, nine smKIs of VEGFR-2 are 
approved for the therapy of various cancers.219 However, VEGFR-2-inhibitors are often 
promiscuous and show significant off-target effects.35 Thus, novel inhibitors and approaches 
for VEGFR-2 research are still highly demanded. 
3,4-Diarylmaleimids were reported to be potent inhibitors of VEGFR-2.190, 191 In the following 
paper photoactivatable prodrugs of VEGFR-2 inhibitors 7 and 8 (Figure 18) were reported. The 
goal was to apply the photocaging technique on potent VEGFR-2 inhibitors and thereby to 
enable spatiotemporal control of VEGFR-2 kinase activity. To best of our knowledge the 
referred compounds were the first caged VEGFR-2 inhibitors reported so far. 
 
Figure 18: Chemical structures of examined VEGFR-2 inhibitors.
190, 191, 194
 3,4-diarylmaleimide 7 and carbazole 8 
correspond to the compounds 1 and 3 in the article “Photoactivatable Caged Prodrugs of VEGFR-2 Kinase 
Inhibitors”, respectively.
194
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The typical workflow for caging protein kinase inhibitors (Figure 12) was applied. The DMNB 
group was utilized as PPG. Two caged derivatives 9 and 10 were yielded (Figure 19). 
 
Figure 19: Chemical structures of photoactivatable VEGFR-2 inhibitors.
194
 Caged 3,4-diarylmaleimide 9 and 
caged carbazole 10 correspond to the compounds 4 and 5 in the article “Photoactivatable Caged Prodrugs of 
VEGFR-2 Kinase Inhibitors”, respectively.
194
 
The loss-off-function of VEGFR-2 inhibitors due to photoprotection could be demonstrated 
both in enzymatic and cellular assays. It was observed that the diarylmaleimide 7 is of limited 
suitability for caging with the DMNB group due to its photoinduced reaction to the respective 
carbazole 8 at the wavelength used for PPG-cleavage. In contrast to the maleimide, the 
photoinduced release of active carbazole inhibitor 8 from its caged derivative 10 succeeded 
fast, clearly and without any observable by-products.194  
The autofluorescence of carbazole 8 and its photoactivatable prodrug 10 was used for 
examination of cellular bioavailability of the compounds. It was demonstrated that the 
insertion of the DMNB PPG does not diminish the cellular uptake of the utilized inhibitors.194 
Dr. Rebecca Horbert synthesized the caged compounds. I performed the characterization of 
all compounds both photochemically and in several in vitro assays such as fluorescence 
microscopy and cell proliferation assays. Furthermore, I wrote the manuscript.  
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3.4 Photoinduced Conversion of Antimelanoma Agent Dabrafenib to 
a Novel Fluorescent BRAFV600E Inhibitor 
Boris Pinchuk, Thorsten von Drathen, Viktoria Opel, and Christian Peifer 
ACS Med. Chem. Lett. 2016, 7 (10), 962–966. 
DOI: 10.1021/acsmedchemlett.6b00340 
 
Dabrafenib (Figure 20), trade name “Tafinlar”, was the second approved selective BRAFV600E 
inhibitor after vemurafenib.101, 220 It shows significant clinical benefits for the treatment of 
BRAFV600E mutated melanoma in comparison to standard chemotherapy.221 Unfortunately, 
similar to vemurafenib, most patients treated with dabrafenib suffer from relapses due to 
acquired resistance within several months of the therapy.222 Even the combination treatment 
of dabrafenib with an MEK inhibitor trametinib does not lead to a durable response.223, 224 
In course of our work on photoactivatable protein kinase inhibitors, we intended to develop 
photoactivatable prodrugs of dabrafenib. First, we examined the UV stability of the parent 
inhibitor. To our great surprise, it was found that dabrafenib is not stable to UV irradiation 
whether in DMSO nor in aqueous solutions. Moreover, even under daylight exposure 
dabrafenib degraded rapidly in solution.196 To the best of our knowledge, this photoinduced 
decomposition was not previously described for the widely applied drug dabrafenib. As key 
consequence of this finding, any work with dabrafenib solutions should be carried out under 
light protection.  
Furthermore, parallel to photoinduced degradation of dabrafenib, formation of a new 
compound was observed. This novel substance was isolated and chemically characterized as 
product of a 6--electrocyclization of dabrafenib (Figure 20).  
The novel compound 11 was extensively characterized both photochemically and in vitro. 
Antiproliferative activity of 11 was demonstrated on melanoma cells. It was supposed that 11 
could be a DNA intercalator, due to its planar aromatic scaffold. However, this hypothesis was 
disproved by several assays. Further extensive in vitro examination including kinase assays, 
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cell proliferation assays, and measurement of antiproliferative activity in NCI60 cell line 
screening225 confirmed that 11 is still a BRAFV600E inhibitor. Compound 11 was determined to 
be more selective but less potent than dabrafenib. Moreover, it was revealed that 11 exhibits 
a strong autofluorescence and therefore can be used for cellular staining. 
 
Figure 20: Photoinduced conversion of the approved smKI dabrafenib to the novel inhibitor 11.
196
 Compound 
11 corresponds to the derivative 2 in the article “Photoinduced Conversion of Antimelanoma Agent Dabrafenib 
to a Novel Fluorescent BRAF
V600E
 Inhibitor”.
196
 
Thorsten von Drathen isolated and chemically characterized compound 11. Viktoria Opel 
performed kinetic measurements of photoinduced conversion of dabrafenib to 11. I 
supervised the whole project and conducted all in vitro studies described in the publication. 
Moreover, I wrote the manuscript for the publication. 
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3.5 Marine derived hamacanthins as lead for the development of 
novel PDGFRβ protein kinase inhibitors 
Boris Pinchuk, Eugen Johannes, Sheraz Gul, Joachim Schlosser, Christoph Schaechtele, Frank 
Totzke and Christian Peifer 
Mar. Drugs 2013, 11, 3209-3223. 
DOI: 10.3390/md11093209 
 
Hamacanthins are deep-sea sponge derived bisindole alkaloids showing a dihydropyrazinone 
ring system (Figure 21).226, 227 Cis-3,4-dihydrohamacanthin B was reported to be a potent and 
selective inhibitor of pyruvate kinase in multidrug resistant bacteria such as MRSA.228 
Moreover, protein kinase inhibitors with the 2(1H)-pyrazinone scaffold were described.229 
Based on these findings, we assumed that the hamacanthine core could be a suitable lead 
structure for the design of smKIs. Therefore, we set out to develop potent VEGFR-2 inhibitors 
with the pyrazinone scaffold.201  
 
Figure 21: Chemical structures of marine derived hamacanthin B
227
 and designed PDFGR inhibitors with 
pyrazine-2(1H)-one core.
201
 Compounds 1 and 12 correspond to the compounds 5 and 8 in the paper “Marine 
derived hamacanthins as lead for the development of novel PDGFRβ protein kinase inhibitors”, respectively. 
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Molecular modelling studies suggested that hamacanthin derivatives possessing the flat 3,5-
diaryl-pyrazin-2(1H)-one core should optimally occupy the ATP binding pocket of VEGFR-2 and 
several derivatives were reported in the following paper.201 Small SAR studies were 
performed to identify suitable aryl substituents in 3- and 5-positions of the pyrazin-2(1H)-one. 
Thereby, a novel microwave-mediated ring closure strategy was utilized for synthesis of new 
compounds.230 The IC50 values of the synthesized inhibitors were determined in a panel of 
protein kinases. Herein, compounds 1 and 12 (Figure 21) were identified as VEGFR-2 
inhibitors. These inhibitors exhibited even stronger potency toward the PDGFRkinase. 
Cellular antiproliferative assays confirmed the cytotoxic activity of 1 and 12 against 
PDGFRdependent cancer cell lines. Therefore, hamacanthin-derived pyrazin-2(1H)-ones 
were used as hit-to-leads for further development of highly potent and selective PDGFRβ-
inhibitors. 
Dr. Eugen Bethke (born Johannes) synthesized all compounds to be tested and performed the 
molecular modeling studies. I evaluated all compounds in cellular assays. 
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3.6 Optimization of potent DFG-in inhibitors of platelet derived 
growth factor receptorβ (PDGF-Rβ) guided by water 
thermodynamics 
Rebecca Horbert,∥ Boris Pinchuk,∥ Eugen Johannes, Joachim Schlosser, Dorian Schmidt, Daniel 
Cappel, Frank Totzke, Christoph Schächtele, and Christian Peifer 
∥Rebecca Horbert and Boris Pinchuk contributed equally to this work. 
J. Med. Chem. 2015, 58, 170−182. 
http://pubs.acs.org/doi/full/10.1021/jm500373x 
(The article is licensed under the terms of the ACS AuthorChoice license) 
 
The following paper describes the development of potent DFG-in PDGFR inhibitors based on 
pyrazin-2(1H)-one compounds reported in the previous article.201 Molecular modeling studies 
combined with extensive SAR examination were performed. For inhibitor optimization 
hydration sites in the binding pocket of PDGFRwere calculated. The displacement of water 
molecules from a hydrophobic binding pocket which can significantly affect the ligand affinity 
was previously described.231 WaterMap technology232, 233 was used to predict thermodynamic 
characteristics of solvent molecules to be displaced. The same technology had already been 
applied by other research groups for design of selective kinase inhibitors.234  
Utilization of WaterMap technology led to design of potent inhibitors of PDGFR.202 The key 
hydration sites in the kinase ATP binding pocket were either displaced or replaced by 
designed ligand moieties. The most potent inhibitor, compound 2 (Figure 22), exhibited an 
IC50 value of 20 nM toward PDGFR and showed a reasonable selectivity in a panel of 300 
wild-type kinases. 
However, the promising characteristics of 2 in enzyme assays could not be fully translated 
into cellular activity. The inhibitor showed only modest inhibition of cancer cell growth as 
demonstrated by cellular proliferation assays. In line with this notion, compound 2 barely 
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inhibited the PDFGR signalling in cells as shown by western blot analysis. The non-effective 
cellular activity of the designed inhibitor might be explained by the compound’s limited 
cellular bioavailability as measured by cellular uptake experiments. Further optimization of 
this compounds series regarding the improvement of ADME properties is therefore essential. 
 
Figure 22: Chemical structure of compound 2, a novel potent DFG-in inhibitor of PDGFR. Compound 2 
corresponds to compound 38 in the article “ Optimization of potent DFG-in inhibitors of platelet derived growth 
factor receptorβ (PDGF-Rβ) guided by water thermodynamics”.
202
 
Nevertheless, rational design of the compound 2 was a clear proof for the usefulness of 
molecular modeling studies including the WaterMap technology for the development and 
optimization of potent protein kinase inhibitors. 
Dr. Rebecca Horbert performed molecular modelling studies. Dr. Daniel Cappel utilized the 
WaterMap technology. Dr. Eugen Bethke (born Johannes) and Dr. Joachim Schlosser 
synthesized the novel compounds. I performed the in vitro characterization of all compounds, 
including cellular proliferation, western blots and cellular uptake experiments. 
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3.7 From Type I to Type II: Design, Synthesis, and Characterization of 
Potent Pyrazin-2-ones as DFG-Out Inhibitors of PDGFRβ 
Eugen Bethke, Boris Pinchuk, Christian Renn, Lydia Witt, Joachim Schlosser, and Christian 
Peifer 
ChemMedChem 2016, 11, 1 – 12. 
DOI: 10.1002/cmdc.201600494 
 
The following publication deals with development and characterization of potent DFG-out 
inhibitors of PDGFR203 The inhibitors were based on the pyrazine-2-one scaffold which was 
successfully utilized for the DFG-in inhibitors described previously.201, 202 This scaffold was 
expanded toward the deep pocket (compare chapter “Kinase domain structure”). Molecular 
modeling studies were used to predict appropriate residues for addressing the deep pocket in 
PDGFRThereby, moieties of known DFG-out inhibitors such as imatinib were combined with 
the pyrazine-2-one core. The designed hybrid inhibitors were accessed by a straightforward 
flexible synthetic route. That way developed compounds were evaluated in cellular 
proliferation assays on PDFGFRdependent cancer cells. Herein, the DFG-out inhibitor 3 
showed a potent cytotoxic activity comparable to positive control imatinib.203 Molecular 
docking studies predicted DFG-out binding mode for compound 3 (Figure 23). Similar to the 
DFG-in inhibitor 2, compound 3 builds two H-bonds to the hinge region and occupies the HR II 
by the trimethoxyphenyl residue. However, compound 3 additionally targets the deep pocket 
in the DFG-out kinase conformation (Figure 23B). 
Both PDGFR inhibitors 2 and 3 possess the same pyrazine-2-one core. This was a valid basis 
for comparison of DFG-in and DFG-out inhibitors possessing the same chemotype and 
biological target in vitro. Extensive biological characterization of these compounds was 
performed. Inhibitors 2 and 3 showed comparable IC50 values in PDGFR kinase activity assay: 
20 nM and 19 nM, respectively. However, the inhibitory activity of compound 3 was 
determined to be time dependent and was shifted to lower IC50 values over incubation 
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period. The slow on/off kinetics of compound 3 was a further evidence for the DFG-out 
binding mode of the kinase inhibitor.235 Cellular proliferation assays revealed that the DFG-
out inhibitor 3 showed stronger cytotoxic activity on PDFGFRdependent cells than its DFG-in 
counterpart 2. TGI values were measured as 55 µM and 552 µM, respectively. Moreover, the 
strong inhibitory activity of compound 3 could be proved in western blot analysis.203 
  
(A) (B) 
Figure 23: Modeled binding modes of developed PDFGR inhibitors.
203, 205
 (A) Ligand interaction diagram of the 
DFG-in inhibitor 2 in the active site of a PDGFR DFG-in homology model.
202
 (B) Ligand interaction diagram of the 
DFG-out inhibitor 3 in the active site of a PDGFR DFG-out homology model.
203
 Inhibitors 2 and 3 correspond to 
the compounds 1 and 5 in the paper “From Type I to Type II: Design, Synthesis, and Characterization of Potent 
Pyrazin-2-ones as DFG-Out Inhibitors of PDGFRβ”, respectively. 
Inhibitors 2 and 3 were submitted for extensive kinase selectivity profiling in both activity-
based (ProQinase, Freiburg, Germany) and affinity-based assays (DiscoverX, San Diego, CA, 
USA). The DFG-out inhibitor 3 was significantly more selective in both assay formats 
compared to the DFG-in inhibitor 2. This finding was in line with the hypothesis about 
enhanced selectivity of DFG-out inhibitors (compare the chapter 1.2.3 “Comparison of DFG-in 
and DFG-out inhibitors”). 
Dr. Eugen Bethke (born Johannes) and Dr. Joachim Schlosser performed the synthesis of the 
reported compounds. Christian Renn236 and I performed the biological characterization of all 
compounds in vitro. 
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4 Summary 
4.1 Photoactivatable prodrugs of kinase inhibitors 
The main focus of the present thesis was on the biological characterization of novel 
photoactivatable prodrugs of smKIs. Aside from the fact that protein kinase inhibitors have 
effectively been applied in the therapy for the last 15 years and the caging technique has 
been utilized in different cellular applications, only very few caged smKIs have been described 
so far.165, 166 Moreover, photoactivatable prodrugs of approved smKIs have not been reported 
yet. 
To the best of my knowledge, our research group developed the first photoactivatable 
prodrugs of an approved smKI.176 The caging concept has successfully been applied on the 
antimelanoma agent vemurafenib.193 A specifically acquired workflow for the caging of kinase 
inhibitors (Figure 12) could be effectively utilized up to animal models. Herein, basic 
hypotheses about the caging concept could be successfully corroborated in vitro: The 
synthesized photoactivatable prodrugs were proved to be inactive in several assays. Light-
induced release of the active inhibitor could be impressively demonstrated in vitro. Recovery 
of activity was proved to be precisely controlled both temporally and spatially. The 
development of photoactivatable prodrugs of vemurafenib was the first proof-of-principle for 
the applicability of caging concept on an approved protein kinase inhibitor. 
Furthermore, in the course of the work on photoactivatable prodrugs of vemurafenib, several 
conclusions could be drawn. Comparison of in vitro data for caged vemurafenib derivatives 
revealed that the caging of the hinge binding site of the inhibitor diminishes the inhibitory 
potency more effectively than the caging of other inhibitor moieties. The azaindole moiety in 
vemurafenib was previously identified to address the hinge region of the target BRAFV600E 
kinase. Thus, the azaindole caged derivative of vemurafenib, compound 4, exhibits 
significantly lower residual activity both in kinase and cellular assays than its sulfonamide 
caged counterpart, compound 13 (Figure 24).237 Moreover, blocking the hinge binder in 
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vemurafenib successfully prevented the affinity to off-target kinases as shown in kinase 
selectivity profiling.193 
 
Figure 24: Chemical structures of photoactivatable prodrugs of vemurafenib.
193
 The azaindole caged compound 
4 and the sulfonamide caged derivative 13 correspond to the compounds 2 and 4 in the published article,
193
 
respectively. 
The cellular toxicity of the photo-cleaved DMNB group could be assessed by usage of two 
model compounds: Boc-protected L-alanine, compound 14, and its DMNB photoactivatable 
derivative, compound 15 (Figure 25). The cleaved DMNB group exhibited moderate 
antiproliferative effects at concentrations above 10 µM, as demonstrated on different cell 
lines.193, 194 Potent kinase inhibitors show strong cytotoxic effects at much lower 
concentrations. Vemurafenib, for instance, already inhibits cellular growth in vitro at 
concentrations around 0.1 µM. Therefore, the toxicity of the cleaved DMNB group might not 
be critical and a wide therapeutic window is feasible. Furthermore, synergistic cytotoxic 
effects of the released active kinase inhibitor and the cleaved PPG toward cancer cells might 
be very interesting for medicinal applications as discussed in the article about caged VEGFR-2 
kinase inhibitors.194 
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Figure 25: Chemical structures of the used model compounds.
193
 Compound 14 is Boc-protected L-alanine and 
corresponds to “Boc-Ala” in the published article. Compound 15 is photoactivatable DMNB-protected derivative 
of the compound 14 and corresponds to “Boc-Ala-DMNB”.
193
 
Motivated by the success of photoactivatable vemurafenib prodrugs in vitro, we set out to 
develop caged prodrugs of other approved smKIs. In the course of our work, we designed 
photoactivatable derivatives of imatinib (Figures 6 and 17).195 Our initial attempts toward 
direct caging of the amide function failed, as only the piperazine caged imatinib derivative, 
compound 16, could be isolated (Figure 26). 
 
Figure 26: Chemical structure of compound 16, the piperazine DMNB-protected imatinib derivative.
195
 
Compound 16 was stable under UV-irradiation and no photoinduced release of imatinib could 
be achieved.195 Only a circuitous synthetic route yielded the desired amide photoprotected 
derivatives of imatinib (Figure 17). Herein, two different PPGs were compared. It was found 
that the DMNB group exhibited more preferable characteristics for photoinduced cleavage 
than the coumarinyl group when attached to imatinib. 
The findings described above underline the influence of both partners on the photoinduced 
reactivation: the inhibitor to be caged and the PPG to be bound to the inhibitor. Rapid and 
clean release of an active inhibitor is a prerequisite for successful usage of caged compounds. 
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Therefore, prior to biological applications, an appropriate PPG should be found for the 
distinct molecular moiety to be caged.  
Interestingly, the reported amide caged derivative of imatinib (compound 5, Figure 17) still 
showed measurable inhibition of PDGFRin a kinase assay.195 This finding is in line with the 
hypothesis that PPG cannot completely eradicate the activity of the caged compound when 
bound to an inhibitor site that is not the hinge binder. However, it is noteworthy to mention 
that even minor impurities or unwanted release of uncaged active inhibitor in the sample can 
cause residual biological activity. These minimal impurities are not always detectable by 
standard chemical analytics but could be sufficient to induce measurable responses in 
sensitive enzyme assays. Therefore, extensive chemical analysis is needed prior to application 
of caged compounds. 
In the course of the work on development of photoactivatable protein kinase inhibitors, 
another significant discovery was made. A lot of kinase inhibitors are not stable to UV 
irradiation used for the cleavage of utilized PPGs. The PDGFR inhibitors possessing the 
pyrazine-2-one core, for instance, underwent a rapid radical degradation when irradiated at 
365 nm.205 Irradiation of VEGFR-2 inhibitors with a 3,4-diarylmaleimid core and of approved 
antimelanoma agent dabrafenib induced in both cases 1,6--electrocyclization followed by 
oxidation.194, 196 The revealed instability strongly restricts the applicability of affected 
inhibitors for caging. Due to these findings, all dabrafenib solutions should be carefully 
protected from light exposure when handled. Strikingly, to the best of my knowledge, the 
demonstrated photoinduced degradation of dabrafenib in solution (Figure 20) has previously 
not been described. Furthermore, the CHMP assessment report states “...the drug substance 
manufactured by the proposed supplier is sufficiently stable...”.238 From my point of view, as 
consequence of demonstrated results the assessment report should be revised. 
The photoinduced 1,6--electrocyclization mentioned above yielded novel compounds with 
interesting characteristics. For example, the autofluorescence of both carbazole compound 8 
(Figure 18) and its DMNB-protected derivative 10 (Figure 19) could be used for proving the 
membrane permeability of DMNB-caged compounds in cellular assays.194 
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Another aspect of the present work was the design and implementation of custom-made light 
sources for biological characterization of novel photoactivatable compounds. In cooperation 
with “Sahlmann Photochemical Solutions” (Bad Segeberg, Germany)239 novel purpose-built 
LED sources were developed. These UV sources were successfully utilized for different in vitro 
assays. 
In summary, the present PhD thesis provided evidence for the applicability of 
photoactivatable prodrugs of approved smKIs at least in vitro. However, several preconditions 
should be fulfilled for successful caging of protein kinase inhibitors. First, the compound to be 
caged has to show distinct stability to the irradiation used for the photoinduced PPG-
cleavage. Second, the biological target of the inhibitor should be known and the inhibitory 
potency should be precisely measurable. Third, the introduction of PPG should completely 
eradicate the activity of the inhibitor. Herein, the hinge binding moiety of the inhibitor should 
be protected. Fourthly, yielded caged compound should exhibit sufficient solubility and 
membrane permeability for cellular applications. Fifthly, the photoinduced release of parent 
compound should be quantitative, rapid and clean. The irradiation used for the deprotection 
should be delivered to the site of action. Therefore, special light emitting sources and light 
delivery systems have to be used. Furthermore, different PPGs can be applied for adjusting 
the wavelength of photoinduced deprotection and for improving bioavailability of caged 
compounds. The latter two points will be discussed in more details in the following chapter 
“Prospects”. The toxicity of the cleavage products of the PPG is not necessarily a problem, as 
was demonstrated on the example of the DMNB group.  
The present work demonstrated that photoactivatable “caged” prodrugs of kinase inhibitors 
enable a precise temporal and spatial control of kinase activity. The caged smKIs might be a 
valuable research tool for investigating the kinase signaling in vitro. 
  
SUMMARY   Chapter 4 
282 
4.2 Novel PDGFR inhibitors 
The second focus of the present work was on the characterization of novel PDGFR inhibitors. 
Potent DFG-in and DFG-out inhibitors possessing the same chemotype were developed and 
compared in vitro. Pyrazine-2-one scaffold from hamacanthin B served as a lead structure. 
Extensive SAR studies were performed. Therefore, a novel synthetic route based on 
microwave-mediated ring closure strategy was used.230 Molecular modeling techniques such 
as WaterMap technology were successfully applied for the prediction of improved potency 
and selectivity of designed compounds. This rational approach led to the development of 
novel DFG-in inhibitors 1 and 2 (Figure 13) with IC50 values in nanomolar range.
201, 202 
Homology model of PDGFRtyrosine kinase was used for molecular modeling.205 The 
modeling studies were applied to predict appropriate residues for addressing the deep pocket 
in PDGFR. For design of novel DFG-out inhibitors the pyrazine-2-one scaffold was combined 
with moieties of known DFG-out inhibitors. These designed hybrid inhibitors were accessed 
by a flexible synthetic route.203 Extensive biological characterization in vitro identified 
compound 3 (Figure 13) as a potent and selective DFG-out inhibitor of PDFGR.  
The most potent agents of DFG-in and DFG-out series, compounds 2 and 3, were extensively 
characterized in vitro. Besides comparable IC50 values in low nanomolar range, several 
differences between the DFG-in inhibitor 2 and its DFG-out counterpart 3 were 
demonstrated. Compound 3 showed a time dependent binding kinetics to the target kinase. 
Moreover, the DFG-out inhibitor 3 was determined to be more potent than 2 both in cellular 
proliferation and western blot assays.203 Furthermore, compound 3 was shown to be more 
selective in different kinase profiling assays than the DFG-in inhibitor 2. This finding was in 
line with the hypothesis about improved selectivity of DFG-out inhibitors. 
To summarize, our rational approach combining molecular modeling studies, novel synthetic 
routes, SAR investigations, and biological characterization led to the development of novel 
PDFGR inhibitors. Especially, the DFG-out inhibitor 3 showed promising in vitro potency and 
selectivity and should be used for further lead optimization.   
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5 Prospects 
5.1 Photoactivatable prodrugs of smKIs 
5.1.1 In vivo testing of photoactivatable prodrugs of vemurafenib 
After having proved the applicability of caging concept in vitro, the photoactivatable prodrugs 
of smKIs should be validated in animal models. Therefore, collaboration between our 
research group and the group of Prof. Dr. Knippschild in Ulm, Germany, was established. 
Together we have planned an extensive animal testing. Caged prodrugs of vemurafenib will 
be tested in a human melanoma xenograft model on Crl:NU(NCr)-Foxn1nu nude mice.240 The 
design of the experiment is based on previously reported preclinical studies of 
vemurafenib.241 Effects of vemurafenib and its caged derivative 4 (Figure 14) on melanoma 
growth will be tested both with and without UV irradiation. Furthermore, another 
photoactivatable prodrug of vemurafenib, compound 17 (Figure 27), will be evaluated in vivo.  
 
Figure 27: Photoactivatable prodrug of vemurafenib 17.
242
 The azaindole moiety of vemurafenib was protected 
by a carboxylic acid analog of the DMNB PPG.
166
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Prodrug 17 is an azaindole caged derivative of vemurafenib similar to compound 4.242 
However, the DMNB protecting group is modified by introduction of a carboxylic acid 
(Figure 27). This modified PPG has previously been utilized to improve the solubility of caged 
compounds.166, 243 Compound 17 has recently been synthesized in our research group and 
showed similar photokinetic characteristics and at the same time highly enhanced solubility 
when compared to prodrug 4.242 
Following questions should be addressed by the projected animal experiments: 
1. Are the caged prodrugs 4 and 17 bioavailable in the xenograft melanoma model?  
2. What dosage of irradiation at 365 nm can be tolerated by animals without side effects? 
3. Are the caged prodrugs 4 and 17 completely pharmacologically inactive when not 
irradiated? 
4. Is it possible to restore the inhibitory activity of vemurafenib toward malignant 
melanoma by directed irradiation of photoactivatable prodrugs in the affected skin 
sites? 
To reduce the number of test animals, several preliminary experiments are planned. The first 
two questions mentioned above should be answered by these preliminary tests. If the 
prodrugs are bioavailable and the irradiation is tolerable, the main experiment will be 
launched. Otherwise the animal testing will be cancelled. In preliminary experiments 
different methods for oral administration of caged compounds should be compared. Herein, 
administration of compounds emulsified in honey should be evaluated.244  
Two appliances were specifically designed and custom-made for the proposed animal 
experiments. First, a mouse restrainer was developed for simultaneous fixing of the mouse 
and irradiation of posterior flanks of the test animal (Figure 28). Secondly, a LED pen for 
controlled irradiation at 365 nm (Figure 29) was custom-made by Sahlmann Photochemical 
Solutions.239 
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Figure 28: Custom-made mouse restrainer with a fixed test mouse. The posterior flank of the animal is 
accessible for irradiation. 
 
 
Figure 29: Custom-made LED pen for irradiation of test animals in the mouse restrainer.
239
 The illumination 
device was designed for the cleavage of the DMNB PPG by irradiation at 365 nm. Irradiation power and time can 
be adjusted by the control module at the top of the picture. 
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5.1.2 Approaches to overcome the limited penetration depth of light  
One of the main challenges of the caging concept is the delivery of light to the target tissue. 
As previously described, the penetration depth of UV/visible light through biological tissues is 
limited and heavily depends on the applied wavelength (Figure 10). Moreover, intense UV 
irradiation can cause damage to biological tissue which may lead to novel malignancies.245, 246 
Therefore, novel PPGs which are cleavable by visible light have been developed. Compounds 
caged by the BODIPY group (Table 1), for instance, can be released with green light irradiation 
at 500 nm.177 However, even light with wavelengths close to 500 nm still has limited biological 
penetration. The maximum tissue permeability can be achieved by light irradiation within the 
so-called “phototherapeutic” or bio-optical window with wavelengths ranging from 650 to 
850 nm.130, 247, 248 On the other hand, the energy provided by these wavelengths is typically 
not sufficient for breaking a chemical bound.249 Several possible solutions for increasing the 
depth of photoactivation have been proposed.250 Below, some of these ideas are named and 
shortly discussed. The approaches originate from the field of the PDT.130 In my opinion, these 
developments might be transferable to applications of caged compounds. 
Novel light-delivery systems 
Delivery of light to the target tissue can be achieved by a technical combination of a powerful 
light source and a suitable fiberoptic delivery system.248 Enormous progress has been made in 
the field of light sources over the last decades.130 Several novel laser and LED sources have 
been developed. Fiberoptic delivery devices compatible with clinical instrumentation such as 
injection needles (Figure 30) or endoscopes have been utilized. A successful combination of a 
diode laser and light delivery through an endoscope has recently been reported in a phase II 
clinical study of PDT of esophageal cancer.251 
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Figure 30: Example of red laser light delivery under the skin by an optical fiber and a needle.
252
  
However, the application of fiber optic systems is limited to near-superficial or endoscopically 
accessible targets. The penetration depth of visible light achieved by direct delivery was 
reported to be about 3 mm underneath the skin.250, 253 Another way for targeted delivery of 
light is irradiation of designated tissue amenable during surgery. Illumination of deeper 
targets that are not operable still remains a great challenge.248, 250  
Two-photon excitation 
Two-photon excitation (TPE) is a simultaneous absorption of two photons that leads to an 
excited energy state.250, 254 It can be used for release of a caged compound. Herein, irradiation 
with a doubled wavelength in comparison to standard photoactivation is used.140, 160 For 
instance, the DMNB PPG with a maximum absorption at 365 nm might be cleaved at 730 nm 
by TPE. One advantage of two-photon uncaging is the possible application of near-infrared 
(NIR) lasers for photoactivation.140 The NIR irradiation has an increased tissue permeability 
compared to UV/visible light. TPE is a nonlinear optical process and requires high light 
intensities. Therefore, tightly focused femtosecond lasers are used as light sources.255 Two-
photon absorption is limited to the area of highest light intensity, thus providing a possibility 
of 3D-control of action.256 This method has been successfully applied for PDT in xenograft 
models, where penetration depths about 2 cm could be achieved.257, 258 
Despite the advantages of deeper penetration and better spatial control, TPE exhibits the 
following key limitation: most described PPGs are not well-suited for two-photon 
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uncaging.140, 160 The quantum yield of TPE can be quantified by the two-photon action cross-
section (TPACS) measured in Goeppert-Mayer units (GM). It is assumed that a TPACS of at 
least 0.1 GM is needed for biological application. The DMNB PPG, for instance, has a TPACS of 
0.035 GM160 and is therefore rather unsuitable for TPE applications. Further development of 
suitable PPGs with increased values of TPACS is required for an effective application of TPE in 
vivo. Another inherent disadvantage of TPE is the requirement of elaborate and expensive 
equipment such as pulsed femtosecond lasers for photoactivation. 
Upconversion systems 
Upconversion (UC) is a process of sequential absorption of several photons that causes 
emission of light with a shorter wavelength than the excitation irradiation.259–261 The process 
leads to an anti-Stokes luminescence.259, 262 Thereby, NIR illumination can be converted to 
higher energy irradiation such as UV or visible light. Absorption of low energy photons is 
comparable to that of TPE described above. However, several significant differences between 
UC and TPE should be highlighted. Real and long life energy levels of lanthanide ions absorb 
the excitation energy during the UC.263 The lanthanide ions are thereby embedded in an 
appropriate dielectric inorganic lattice. These guest-host systems are called upconversion 
nanoparticles (UCNPs) when their size is less than 100 nm.263 On the contrary, TPE utilizes 
organic molecules and involves virtual energy levels. As mentioned above, this explains the 
need of simultaneous absorption of two photons and therefore the requirement of high 
energetic pulsed femtosecond lasers for PTE.254 However, due to sequential absorption, no 
pulsed lasers are needed for UC, low-cost continuous-wave diode lasers are sufficient. 
Another advantage of UC is a much higher efficiency compared to TPE.263 
UCNPs exhibit several advantageous optical characteristics such as high signal-to-noise ratio 
of emitted radiation, large anti-Stokes shifts, narrow emission bandwidths, no blinking, and 
no photobleaching.250, 263 Moreover, the upconverting range of UCNPs can be easily 
modulated by directed chemical design. Due to the fact that NIR radiation is within the 
phototherapeutic window, UCNPs can be used for converting NIR into local UV radiation in 
deeper tissues.250 These unique properties of UCNPs make them highly interesting for 
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biological applications. Meanwhile, several studies have been reported where UCNPs have 
been utilized for PDT, photothermal therapy or drug delivery. Moreover, UC has also been 
used for the cleavage of PPGs. Several examples of applied UC for photoactivation of caged 
compounds in deeper tissue have been described.263–266 Herein, the caged compounds were 
either loaded in the pores of silica coated UCNPs264 or covalently bound to thiolated silanes 
on the surface of coated UCNPs.266 The latter concept was successfully proved using the 
photocaged luciferin (Figure 31). 
 
Figure 31: Proof-of-principle for the photolysis of caged D-luciferin by utilizing UCNPs coated with thiolated 
silane.
266
 1-(2-nitrophenyl)ethyl caged luciferin was covalently bound to the UCNP by a linker. The excitation NIR 
radiation was upconverted by UCNPs to UV light that cleaved the PPG. The released luciferin was recognized by 
a luciferase (fLuc enzyme) and caused measurable bioluminescence. 
The proof-of-principle study demonstrated that utilized UCNPs were cell-penetrating and 
exhibited no significant cytotoxicity in cellular assays.266 NIR irradiation was also well 
PROSPECTS   Chapter 5 
290 
tolerated. Furthermore, UCNPs might be conjugated with a tumor-targeting agent achieving 
enhanced tumor selectivity.267–269 
Despite all favorable characteristics of UC described above, several challenges have to be met 
prior possible medical application of UCNPs. The conversion efficiency of UCNPs still remains 
rather insuffienct.270 This poor efficacy causes prolonged irradiation times needed for 
complete uncaging.266 Moreover, the loading capacity of UCNPs also remains limited.263 
Development of highly efficient NIR-to-UV converting nanoparticles with enhanced quantum 
yield is therefore necessary. 
Another very important issue to be addressed is the biocompatibility of UCNPs.271 The used 
lanthanides are not found in biological systems under physiological conditions. UCNPs are not 
biodegradable in vivo. Therefore, an efficient clearance of UCNPs is a precondition for clinical 
applications of these particles.263 To date, only few investigations regarding possible toxicity 
of lanthanide doped nanoparticles have been performed so far. The in vivo toxicity of UCNPS 
has been systematically examined only in mouse, worms and zebrafish.272 Herein, evidence 
for possible dose-dependent toxicity was provided.272 Further in vivo investigations of 
possible UCNPs toxicity are highly required.263, 270, 272 
X-ray excitation 
The NIR radiation permeates deeper into biological tissue than UV/visible light, however the 
penetration depth of NIR is limited too. Usually, maximum depths about one or two 
centimeters can be achieved.171 The highest reported NIR penetration was 3 cm in vivo.273 To 
address targets noninvasively deeper than that, application of high-energy X-rays is 
feasible.274 Since their discovery in 1895, X-rays have widely been used for medical imaging 
and radiotherapy. Besides great biological permeability, X-rays offer a possibility of 
distinguished spatial resolution up to 10 nm.275 
X-ray irradiation cannot directly cleave a photoremovable protecting group. Therefore, 
scintillator materials that convert the X-rays to UV/visible light are necessary for 
photoactivation of caged compounds. Progress in nanotechnology led to the development of 
nanoparticles that can be used for this purpose.274 Several examples of scintillating 
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nanoparticles (ScNPs) have already been utilized as energy mediators for down conversion of 
X-ray to UV/visible light.274 ScNPs are materials with a wide band gap such as lanthanide 
doped nanoparticles.276, 277 Meanwhile, there are several reports where scintillators have 
successfully been utilized for PDT,278–280 optical imaging281 or PUVA.282 An overview of UVA 
(UV in the range of 315 – 400 nm) emitting ScNPs can be found in literature.282 Furthermore, 
besides lanthanide doped nanoparticles other scintillating materials have been reported, for 
instance: zinc oxide nanoparticls,283, 284 copper doped zinc sulfide nanoparticles,285 and 
quantum dots.286, 287 ScNPs conjugated with targeting molecules have been developed to 
selectively address tumor cells.274, 279 
Similar to UCNPs, ScNPs might be loaded or conjugated with a caged prodrug. Different 
loading strategies for photosensitizers used in PDT have recently been described.274 Thus, the 
concept of coated UCNPs conjugated to a photoactivatable compound (Figure 31) might be 
transferred to ScNPs. Herein, X-ray irradiation might be converted to UV/visible light by 
scintillating nanoparticles. The emitted UV might cleave a PPG from the conjugated caged 
prodrug. As consequence, an active pharmaceutical ingredient might be released. X-ray 
excitation would enable addressing deeper targets with higher spatiotemporal resolution 
than irradiation by NIR. Compared to X-ray induced PDT, this concept would be advantageous 
in respect to enhanced selectivity of utilized kinase inhibitors. Furthermore, the hypoxic 
tumor environment as a typical challenge for PDT should not be a problem for the released 
smKIs. 
To the best of my knowledge, the concept of using ScNPs to convert X-rays into UV/visible 
irradiation for reactivating photoactivatable prodrugs has not been evaluated yet. From my 
point of view, this approach would enable a smart possibility for combination of radiotherapy 
and precisely regulated release of active antitumor agents such as smKIs. Due to synergistic 
antitumor efficacy of X-rays and released smKIs, better therapeutic outcome might be 
possible. Moreover, lower dosage of harmful X-rays might be utilized. Of course, the concept 
of utilizing ScNPs for photoactivation of caged compounds is only an idea at this time. Several 
preconditions have to be met prior to biological applications of this approach: ScNPs with 
high scintillating efficacy and emission matching the wavelengths for PPG cleavage should be 
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evaluated. Caged prodrugs have to be effectively loaded or conjugated to scintillating 
materials. The successful release of active compounds upon X-ray irradiation should be 
proved under biological conditions. Last but not least, pharmacokinetic properties and 
toxicity profiles of utilized ScNPs should be extensively investigated prior to potential medical 
applications. 
Cerenkov radiation 
Cerenkov radiation (CR) occurs when a charged particle ( or - particle) travels through a 
dielectric medium at a speed faster than light in this medium.250, 288 Medium molecules 
become thereby polarized into excited energy states. When medium molecules relax back to 
the ground state they emit the so called Cerenkov luminescence.288, 289 CR is emission of light 
within a broad and continuous wavelength range (200 – 1000 nm).250 The intensity of CR is 
proportional to the frequency of emitted light. Therefore, the major part of luminescence 
occurs in UV and blue spectrum. Cerenkov radiation was first described in 1934.290 This 
physical phenomenon is responsible for the known blue glowing in nuclear reactors 
(Figure 32). 
 
Figure 32: Cerenkov radiation in a reactor core.
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Cerenkov radiation has been used in physics for particle identification292 or in astrophysics for 
detection of high-energy gamma-rays.293 More recently, CR has been successfully applied in 
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several studies for optical imaging in vivo.270, 288, 294–297 For instance, CR could be utilized for 
imaging of thyroid gland of a patient who was treated with 131I (Figure 33).298 Furthermore, 
Cerenkov radiation has recently been utilized in combination with titanium dioxide as a 
nanophotosensitizer for PDT in a mouse xenograft model of fibroblastic sarcoma.299 Herein, 
fluorodeoxyglucose 18FDG was used as a source. By coating the nanoparticles with 
transferrin, tumor specific accumulation could be achieved.299 
 
Figure 33: Proof-of-principle for applicability of CR for in vivo imaging in human.
298
 (a) CR of a thyroid gland of a 
patient treated with 
131
I. (b) The overlay between the photographic image and the CR image of the patient.
298
  
Successful usage of radioisotopes for biological imaging and induced PDT proved the 
applicability of Cerenkov radiation in vivo. A very interesting approach might be the 
application of CR for uncaging of photoactivatable prodrugs. The CR-induced release of caged 
compounds has already been impressively proved in 2012.300 Herein, a photoactivatable 
derivative of luciferin (Figure 34) was uncaged by administration of 18FDG in a mouse breast 
cancer model expressing luciferase.300 
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Figure 34: Uncaging of photoactivatable derivative of luciferin with Cerenkov radiation induced by 
18
FDG. 
Adapted and modified from the original publication.
300
 
In this proof-of-concept study, the CR-induced release of luciferin could be monitored in real-
time. In vivo experiments impressively demonstrated that the CR-induced uncaging is much 
more efficient in deeper tissue than the photoactivation by UV irradiation due to limited 
penetration of UV.300 This study produced a strong evidence for applicability of CR for 
reactivation of caged compounds in vivo. However, to the best of my knowledge, there are no 
studies utilizing CR for uncaging of photoactivatable prodrugs.  
Application of CR for uncaging of photoactivatable smKIs might offer some advantage in 
therapy because many radiotracers that emit CR have already been approved for clinical 
usage.274 Tissue specific release of active inhibitors might be possible by usage of specific or 
modified tracers.299, 300 However, the approach might be limited by low intensity of 
CR.250, 274, 288 A possible solution might be the utilization of more efficient -emitters such as 
90Y and 89Zr.274  
Another possibility for increasing the efficiency of CR for targeted uncaging of smKIs might be 
the application of linear accelerators (LINACs). LINACs are already used in cancer 
therapy.301, 302 Several studies provided evidence that irradiation with LINACs produce 
CR.303, 304 Herein, Cerenkov luminescent emission from LINACs is much greater than CR from 
beta radionuclides.288 An interesting approach might be the application of particle 
accelerators that are currently being used for proton therapy. Particle beams can reach 
deeper tissues and can be better focused on tumors than X-ray beams.305 Furthermore, CR 
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from the proton beams has already been demonstrated.306 This Cerenkov luminescence might 
be potentially used for cleavage of PPGs from caged compounds. However, to the best of my 
knowledge, no studies utilizing this approach have been performed yet. 
From my point of view, the application of highly-focused particle beams for controlled 
activation of caged smKIs might be a unique possibility to combine radiotherapy with 
targeted pharmacological therapy of cancer. Due to possible synergistic effects, the applied 
radiation dose might be decreased. Of course, I am well aware that this idea is speculative. 
Many experiments regarding the cleavage efficacy of emitted CR and possible toxicities have 
to be carried out. Currently, our research group is working on investigation of applicability of 
CR-induced release of caged compounds. Herein, CR emitted both by radionuclides such as 
18F and by ionizing beams should be evaluated. Therefore, collaboration with the department 
for radiation therapy at university hospital in Kiel, Germany, has been established. 
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5.1.3 Concluding remarks 
Photoactivatable prodrugs of smKIs represent an exciting option for basic research in the 
kinase inhibitors field. Spatiotemporal control of kinase action by irradiation of caged 
inhibitors in vitro has been demonstrated in the course of the present PhD work. The 
described prodrugs might be a powerful tool for studying the regulation and kinetics of 
protein phosphorylation. Furthermore, photoactivatable prodrugs of smKIs might find usage 
in clinical applications. Novel approaches to release the active compounds in deeper tissues 
described above might enable novel therapeutic possibilities. For instance, an abrupt rise of 
active inhibitor concentration in targeted tumor might be feasible due to controlled 
irradiation. As a consequence, systemic side effects and resistance development should be 
minimized. A combination of radiotherapy and induced release of active smKIs might be 
another promising option.  
However, a lot of profound basic research is required prior to clinical applications of 
photoactivatable prodrugs of smKIs. Pharmacokinetic and toxicological characteristics of 
caged compounds should be surveyed in greater detail. Moreover, physicochemical 
properties such as aqueous solubility of caged prodrugs should be improved prior to in vivo 
applications. Herein, utilization of novel PPGs with enhanced solubility such as the BODIPY 
PPG might be useful. Furthermore, the biological effects of the cleaved PPG should be 
examined in more detail. A further aspect that should be investigated prior to clinical 
applications is the metabolic stability of caged compounds.  
To summarize, caged prodrugs of smKIs might enable novel opportunities both in basic 
research and in therapeutic applications. However, multidisciplinary research and 
development in a collaboration of pharmacists, chemists, biochemists, physicians and 
biomedical engineers is needed for future implementation of photoactivatable prodrugs in 
therapy. Nevertheless, novel developments both in chemistry and nanotechnology allow a 
reasonable optimistic look into the future.  
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5.2 PDGFRinhibitors
In the course of the present work novel potent PDGFRinhibitors were developed and 
characterized in vitro. It was demonstrated that the DFG-out inhibitor 3 was both more 
selective and more potent in cellular assays than the DFG-in inhibitor 2 (Figure 13). Further 
development is needed to translate the promising in vitro potency in useful activity in vivo. 
Due to its enhanced selectivity, the DFG-out inhibitor 3 should be considered for further lead 
optimization. Therefore, improvement of physicochemical and pharmacokinetic properties 
should be pursued. Thus, water solubility and bioavailability of the compound 3 should be 
increased prior to in vivo testing. Extensive profiling in a cancer cell line panel, like the NCI60 
panel, might be performed for identifying promising tumor targets. Usage of xenograft animal 
models should assess the applicability of novel inhibitors for possible treatment options. 
Furthermore, the results of in vivo validation should be compared with hitherto approved 
PDGFRinhibitors. 
The in vitro characterization of herein developed PDGFRinhibitors led to the assumption 
that DFG-out inhibitors have more preferable pharmacological characteristics than the DFG-in 
inhibitors. This hypothesis should be critically evaluated by comparing inhibitors with similar 
chemotype for other kinase targets. Furthermore, it should be examined whether preferable 
in vitro properties of DFG-out inhibitors can be transferred into improved in vivo 
characteristics. 
Methodology applied in the course of the present work, such as utilizing the WaterMap 
technology for molecular docking experiments and novel developed synthetic routes might be 
used for the development of further protein kinase inhibitors.  
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7 Appendix 
7.1 List of Abbreviations 
18FDG  2-deoxy-2-(18F)fluoro-D-glucose 
Ab  antibody 
ABL  Abelson tyrosine kinase 
ADME  absorption, distribution, metabolism, and excretion 
AGC  family group of protein kinases A, G, and C 
ALL  acute lymphoid leukemia  
AP  adenine pocket  
ATP  adenosine triphosphate 
BCR  breakpoint cluster region 
Boc  tert-butyloxycarbonyl protecting group 
BSA  bovine serum albumin 
C. elegans Caenorhabditis elegans 
CAMK  calcium/calmodulin-dependent protein kinase 
CDK  cyclin-dependent kinase 
CHMP  Committee for Medicinal Products for Human Use 
CK1  casein kinase 1 
c-Kit  mast/stem cell growth factor receptor 
CLK  CDC2-like kinase 
CMGC  protein kinase group containing CDK, MAPK, GSK3 and CLK families 
CML  chronic myeloid leukemia 
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CR  Cerenkov radiation 
DMNB  4,5-dimethoxy-2-nitrobenzyl 
DMNP  1-(4,5-dimethoxy-2-nitrophenyl)  
DMSO  dimethyl sulfoxide 
DPBS  Dulbecco's phosphate-buffered saline 
e.g.  exempli gratia, for example 
EGFR  epidermal growth factor receptor 
ERK  extracellular signal–regulated kinase 
GIST  gastrointestinal stromal tumor 
GSK3  glycogen synthase kinase 3 
H-bond hydrogen bond 
HP I  hydrophobic pocket I,  
HR II  hydrophobic region II 
IC50  half maximal inhibitory concentration 
JAK  janus kinase 
LED  light emitting diode 
LINACs  linear particle accelerators 
mAb  monoclonal antibody 
MAPK  mitogen-activated protein kinase 
MEK  mitogen-activated protein kinase kinase 
MRSA  methicillin-resistant Staphylococcus aureus 
mTOR  mammalian target of rapamycin 
NCI  national cancer institute, USA 
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NIR  near-infrared 
PBR  phosphate binding region 
PDGFR  platelet-derived growth factor receptor 
PDT  photodynamic therapy 
PKA  protein kinase A 
PKC  protein kinase C 
PPG  photoremovable or photocleavable protecting group 
PUVA  psoralen and ultraviolet A 
ROCK  rho-associated protein kinase 
ROS  reactive oxygen species 
RTK  receptor tyrosine kinase 
SAR  structure-activity relationship 
ScNPs  scintillating nanoparticles 
SH2  Src Homology 2 
SI  supplementary information for a paper 
smKI  small molecule kinase inhibitors 
SP  sugar pocket 
STE  protein kinase group, homologs of yeast sterile 7, 11 and 20 kinases 
TGI  total growth inhibition 
TK  tyrosine kinases 
TKL  tyrosine kinase-like 
TPACS  two-photon action cross-section 
TPE  two-photon excitation 
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UCNPs  upconversion nanoparticles 
UP  upconversion 
UV  ultraviolet 
UVA  ultraviolet A 
VEGFR  vascular endothelial growth factor receptor  
v-Src  gene found in Rous sarcoma virus 
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7.2 List of Figures 
Figure 1: Phylogenetic tree of the human kinome. Seven major protein kinase groups can be 
distinguished: TKL, STE, CK1, AGC, CAMK, CMGC and TK. Kinases discussed more in this work 
are labeled with bold red letters. The phylogenetic tree is adapted from cell signaling 
technology.26 ................................................................................................................................ 4 
Figure 2: Schematic presentation of the kinase domain of VEGFR-2 (PDB code: 3B8R).45 This 
and subsequent figures showing 3D protein structures were visualized using Maestro 10.4.46 
The N-terminus is colored purple and the C-terminus is blue. The hinge region is depicted in 
green. ............................................................................................................................................ 6 
Figure 3: Schematic model of the ATP-binding site in an active kinase. The representation is 
based on the crystallized structure of ERK2 kinase in complex with ATP (PDB code: 4GT3).54 
Amino acid residue glutamine 103 (Glu103) was indicated as the gatekeeper in accordance to 
previous studies.55 The pharmacophore model by Traxler and Furet was applied.43, 50 Maestro 
10.4 was used for visualization.46 Only key residues are shown for better clarity. ATP is 
depicted with ball and sticks. The amino acid residues are represented as thin tubes. H-Bonds 
are indicated by yellow dashed lines. HR II = hydrophobic region II, AP = adenine pocket, HP I 
= hydrophobic pocket I, SP = sugar pocket, PBR = phosphate binding region. ........................... 8 
Figure 4: Binding site in the VEGFR-2 kinase domain in different DFG conformations.59 The 
representations were visualized using Maestro 10.446 and are according to the noted PDB 
codes. (A) DFG-in conformation is shown (PDB code: 3B8R).45 The phenylalanine residue 
Phe1047 blocks the deep pocket. The adenine pocket is exposable for ATP (blue oval). (B) 
DFG-out conformation is depicted (PDB code: 3EWH).60 The phenylalanine residue Phe1047 is 
now rearranged and blocks access to the adenine pocket for ATP. The deep pocket (red oval) 
can now be addressed by inhibitors. ........................................................................................... 9 
Figure 5: The regulatory (purple) and catalytic (yellow) spines in the active PKA kinase.28 The 
presentation is in accordance to Kornev et al.62 and is based on the PDB code: 1ATP.63 
Disruption of these spines drives the inactive kinase conformation. ........................................ 10 
Figure 6: Chemical structure of imatinib, the first approved kinase inhibitor for cancer 
treatment. .................................................................................................................................. 12 
Figure7: Schematic representation of irreversible photoactivation (uncaging). A 
photoremovable protecting group (PPG, purple star in the figure) is covalently bound to a 
compound (blue triangle). As consequence, the compound is caged and inactive. After 
irradiation with light at appropriate wavelength the PPG is cleaved and the released active 
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compound can bind to its target. Thus, biological effects can be induced upon irradiation. The 
activation is irreversible. Some graphical elements used in the visualization such as 
membrane and receptor were adopted from Servier Medical Art.142....................................... 20 
Figure 8: Schematic representation of reversible photoswitching.130 An inactive compound 
(blue square) can be reversibly switched to its active isomer (dark blue triangle) that can 
interact with its biological target. The activation is reversible. The backward reaction can be 
induced by irradiation at a different wavelength. Some graphical elements used in the 
visualization were adopted from Servier Medical Art.142 .......................................................... 21 
Figure 9: Schematic representation of optogenetics.130 A genetically modified, 
photoresponsive protein, mostly an ion channel can be activated by light to evoke a biological 
effect. Some graphical elements used in the visualization were adopted from Servier Medical 
Art.142 .......................................................................................................................................... 22 
Figure 10: The penetration depth of different light wavelengths into biological tissue.172, 173
 .................................................................................................................................................... 25 
Figure 11: Schematic representation of release mechanism of o-nitrobenzyl caged 
compounds.176, 178, 185, 186 “X” stands for the released compound. ........................................... 28 
Figure 12: Workflow for the caging of protein kinase inhibitors.176 ........................................ 29 
Figure 13: Hamacanthin B as lead for the development of PDGFRinhibitors with pyrazine-
2(1H)-one scaffold. Comparison between DFG-in inhibitors 1 and 2 and DFG out inhibitor 3 
was one of the aims in the present thesis. ................................................................................ 32 
Figure 14: Chemical structures of vemurafenib and its photoactivatable prodrug 4. The 
caged compound 4 corresponds to the caged prodrug 2 in the article “Photoactivatable 
Prodrugs of Antimelanoma Agent Vemurafenib”. ..................................................................... 84 
Figure 15: Phospho-ERK staining of melanoma SKMel13 cells after incubation with 
vemurafenib and the photoactivatable prodrug 4. The top four rows of a 96-well-plate with 
treated cells are shown. The phosphorylated ERK is immunostained with a combination of 
primary and secondary Ab. The latter one is conjugated to a red fluorescent dye. The 
experiment was performed in dark without UV irradiation. ..................................................... 85 
Figure 16: Phospho-ERK staining of melanoma SKMel13 cells after incubation with DMSO 
and the photoactivatable prodrug 4 of vemurafenib. The bottom four rows of the same 96-
well-plate as in Figure 15 are shown. These rows were irradiated at 365 nm with 0.9 W for 
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five minutes. The phosphorylated ERK is immunostained with a combination of a primary and 
a secondary Ab. The latter one is conjugated to a red fluorescent dye. ................................... 86 
Figure 17: Chemical structures of photoactivatable prodrugs of imatinib.193 DMNB- caged 
imatinib derivative 5 and coumarin-4-ylmethyl caged derivative 6 correspond to the 
compounds 2 and 3 in the article “Design, Synthesis, and Characterization of a 
Photoactivatable Caged Prodrug of Imatinib”, respectively.193 ................................................. 88 
Figure 18: Chemical structures of examined VEGFR-2 inhibitors.190, 191, 194 3,4-diarylmaleimide 
7 and carbazole 8 correspond to the compounds 1 and 3 in the article “Photoactivatable 
Caged Prodrugs of VEGFR-2 Kinase Inhibitors”, respectively.194 ............................................. 113 
Figure 19: Chemical structures of photoactivatable VEGFR-2 inhibitors.194 Caged 3,4-
diarylmaleimide 9 and caged carbazole 10 correspond to the compounds 4 and 5 in the article 
“Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors”, respectively.194 ............... 114 
Figure 20: Photoinduced conversion of the approved smKI dabrafenib to the novel inhibitor 
11.196 Compound 11 corresponds to the derivative 2 in the article “Photoinduced Conversion 
of Antimelanoma Agent Dabrafenib to a Novel Fluorescent BRAFV600E Inhibitor”. ................. 140 
Figure 21: Chemical structures of marine derived hamacanthin B227 and designed PDFGR 
inhibitors with pyrazine-2(1H)-one core.201 Compounds 1 and 12 correspond to the 
compounds 5 and 8 in the paper “Marine derived hamacanthins as lead for the development 
of novel PDGFRβ protein kinase inhibitors”, respectively. ...................................................... 171 
Figure 22: Chemical structure of compound 2, a novel potent DFG-in inhibitor of PDGFR. 
Compound 2 corresponds to compound 38 in the article “Optimization of potent DFG-in 
inhibitors of platelet derived growth factor receptorβ (PDGF-Rβ) guided by water 
thermodynamics”.202 ................................................................................................................ 190 
Figure 23: Modeled binding modes of developed PDFGR inhibitors.203, 205 (A) Ligand 
interaction diagram of the DFG-in inhibitor 2 in the active site of a PDGFR DFG-in homology 
model.202 (B) Ligand interaction diagram of the DFG-out inhibitor 3 in the active site of a 
PDGFR DFG-out homology model.203 Inhibitors 2 and 3 correspond to the compounds 1 and 
5 in the paper “From Type I to Type II: Design, Synthesis, and Characterization of Potent 
Pyrazin-2-ones as DFG-Out Inhibitors of PDGFRβ”, respectively. ............................................ 246 
Figure 24: Chemical structures of photoactivatable prodrugs of vemurafenib.193 The 
azaindole caged compound 4 and the sulfonamide caged derivative 13 correspond to the 
compounds 2 and 4 in the published article,193 respectively. ................................................. 278 
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Figure 25: Chemical structures of the used model compounds.193 Compound 14 is Boc-
protected L-alanine and corresponds to “Boc-Ala” in the published article. Compound 15 is 
photoactivatable DMNB-protected derivative of the compound 14 and corresponds to “Boc-
Ala-DMNB”.193 .......................................................................................................................... 279 
Figure 26: Chemical structure of compound 16, the piperazine DMNB-protected imatinib 
derivative.195 ............................................................................................................................ 279 
Figure 27: Photoactivatable prodrug of vemurafenib 17.242 The azaindole moiety of 
vemurafenib was protected by a carboxylic acid analog of the DMNB PPG.166 ...................... 283 
Figure 28: Custom-made mouse restrainer with a fixed test mouse. The posterior flank of the 
animal is accessible for irradiation. .......................................................................................... 285 
Figure 29: Custom-made LED pen for irradiation of test animals in the mouse restrainer.239  
The illumination device was designed for the cleavage of the DMNB PPG by irradiation at 
365 nm. Irradiation power and time can be adjusted by the control module at the top of the 
picture. ..................................................................................................................................... 285 
Figure 30: Example of red laser light delivery under the skin by an optical fiber and a 
needle.252 .................................................................................................................................. 287 
Figure 31: Proof-of-principle for the photolysis of caged D-luciferin by utilizing UCNPs coated 
with thiolated silane.266 1-(2-nitrophenyl)ethyl caged luciferin was covalently bound to the 
UCNP by a linker. The excitation NIR radiation was upconverted by UCNPs to UV light that 
cleaved the PPG. The released luciferin was recognized by a luciferase (fLuc enzyme) and 
caused measurable bioluminescence. ..................................................................................... 289 
Figure 32: Cerenkov radiation in a reactor core.291 ................................................................ 292 
Figure 33: Proof-of-principle for applicability of CR for in vivo imaging in human.298 (a) CR of 
a thyroid gland of a patient treated with 131I. (b) The overlay between the photographic image 
and the CR image of the patient.298 ......................................................................................... 293 
Figure 34: Uncaging of photoactivatable derivative of luciferin with Cerenkov radiation 
induced by 18FDG. Adapted and modified from the original publication.300........................... 294 
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